WO2022095965A1 - 四氮唑类衍生物、制备、含其的药物组合物及其应用 - Google Patents
四氮唑类衍生物、制备、含其的药物组合物及其应用 Download PDFInfo
- Publication number
- WO2022095965A1 WO2022095965A1 PCT/CN2021/129024 CN2021129024W WO2022095965A1 WO 2022095965 A1 WO2022095965 A1 WO 2022095965A1 CN 2021129024 W CN2021129024 W CN 2021129024W WO 2022095965 A1 WO2022095965 A1 WO 2022095965A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tetrazol
- phenyl
- pentan
- bromo
- methyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 150000003536 tetrazoles Chemical class 0.000 title abstract 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 180
- 239000003814 drug Substances 0.000 claims abstract description 39
- 229940079593 drug Drugs 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims description 46
- -1 nitro, hydroxyl Chemical group 0.000 claims description 43
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 28
- 239000012453 solvate Substances 0.000 claims description 23
- 230000003287 optical effect Effects 0.000 claims description 21
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 14
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 9
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 8
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 230000002785 anti-thrombosis Effects 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 230000002633 protecting effect Effects 0.000 claims description 5
- 239000007818 Grignard reagent Substances 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 230000004087 circulation Effects 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 150000004795 grignard reagents Chemical class 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 claims description 4
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 4
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- LAXASHWYFSCETM-UHFFFAOYSA-N 1-[2-(2H-tetrazol-5-yl)phenyl]butan-1-ol Chemical compound N1N=NN=C1C1=C(C=CC=C1)C(CCC)O LAXASHWYFSCETM-UHFFFAOYSA-N 0.000 claims description 2
- ZHXYOQVVYYGENZ-UHFFFAOYSA-N 1-[2-(2H-tetrazol-5-yl)phenyl]hexan-1-ol Chemical compound CCCCCC(C1=CC=CC=C1C2=NNN=N2)O ZHXYOQVVYYGENZ-UHFFFAOYSA-N 0.000 claims description 2
- AVSPLYQUXHRKEG-UHFFFAOYSA-N 1-[2-(2H-tetrazol-5-yl)phenyl]pentan-1-ol Chemical compound N1N=NN=C1C1=C(C=CC=C1)C(CCCC)O AVSPLYQUXHRKEG-UHFFFAOYSA-N 0.000 claims description 2
- DLOLVBPSNCAJQN-UHFFFAOYSA-N 1-[4-bromo-2-(2H-tetrazol-5-yl)phenyl]butan-1-ol Chemical compound BrC1=CC(=C(C=C1)C(CCC)O)C1=NN=NN1 DLOLVBPSNCAJQN-UHFFFAOYSA-N 0.000 claims description 2
- ZMPNCQWDIGNPGM-UHFFFAOYSA-N 1-[4-bromo-2-(2H-tetrazol-5-yl)phenyl]hexan-1-ol Chemical compound CCCCCC(C1=C(C=C(C=C1)Br)C2=NNN=N2)O ZMPNCQWDIGNPGM-UHFFFAOYSA-N 0.000 claims description 2
- QBVFJSYWFVRUFG-UHFFFAOYSA-N 1-[4-bromo-2-(2H-tetrazol-5-yl)phenyl]pentan-1-ol Chemical compound BrC1=CC(=C(C=C1)C(CCCC)O)C1=NN=NN1 QBVFJSYWFVRUFG-UHFFFAOYSA-N 0.000 claims description 2
- BZEAPBWMFKJHNK-UHFFFAOYSA-N 1-[4-chloro-2-(2H-tetrazol-5-yl)phenyl]butan-1-ol Chemical compound ClC1=CC(=C(C=C1)C(CCC)O)C1=NN=NN1 BZEAPBWMFKJHNK-UHFFFAOYSA-N 0.000 claims description 2
- SGMKXKFTNFCNGQ-UHFFFAOYSA-N 1-[4-chloro-2-(2H-tetrazol-5-yl)phenyl]hexan-1-ol Chemical compound CCCCCC(C1=C(C=C(C=C1)Cl)C2=NNN=N2)O SGMKXKFTNFCNGQ-UHFFFAOYSA-N 0.000 claims description 2
- DTTARXDGGBQTNS-UHFFFAOYSA-N 1-[4-chloro-2-(2H-tetrazol-5-yl)phenyl]pentan-1-ol Chemical compound ClC1=CC(=C(C=C1)C(CCCC)O)C1=NN=NN1 DTTARXDGGBQTNS-UHFFFAOYSA-N 0.000 claims description 2
- GHKSINMGIUBQIQ-UHFFFAOYSA-N 1-[4-fluoro-2-(2H-tetrazol-5-yl)phenyl]butan-1-ol Chemical compound FC1=CC(=C(C=C1)C(CCC)O)C1=NN=NN1 GHKSINMGIUBQIQ-UHFFFAOYSA-N 0.000 claims description 2
- BWZYEIFYVKHAGF-UHFFFAOYSA-N 1-[4-fluoro-2-(2H-tetrazol-5-yl)phenyl]hexan-1-ol Chemical compound CCCCCC(C1=C(C=C(C=C1)F)C2=NNN=N2)O BWZYEIFYVKHAGF-UHFFFAOYSA-N 0.000 claims description 2
- ULMDNBFPIYUJDA-UHFFFAOYSA-N 1-[4-fluoro-2-(2H-tetrazol-5-yl)phenyl]pentan-1-ol Chemical compound FC1=CC(=C(C=C1)C(CCCC)O)C1=NN=NN1 ULMDNBFPIYUJDA-UHFFFAOYSA-N 0.000 claims description 2
- DESWSUOUBWHWOC-UHFFFAOYSA-N BrC1=CC(=C(C=C1)C(CCCC)O)C1=NN=NN1C Chemical compound BrC1=CC(=C(C=C1)C(CCCC)O)C1=NN=NN1C DESWSUOUBWHWOC-UHFFFAOYSA-N 0.000 claims description 2
- BZRVAAIYSRFKAW-UHFFFAOYSA-N BrC1=CC=C(C(=N1)C1=NN=NN1)C(CCCC)O Chemical compound BrC1=CC=C(C(=N1)C1=NN=NN1)C(CCCC)O BZRVAAIYSRFKAW-UHFFFAOYSA-N 0.000 claims description 2
- SFEMQPJIXFXMNO-UHFFFAOYSA-N BrC1=CC=C(C(=N1)C1=NN=NN1C)C(CCCC)O Chemical compound BrC1=CC=C(C(=N1)C1=NN=NN1C)C(CCCC)O SFEMQPJIXFXMNO-UHFFFAOYSA-N 0.000 claims description 2
- PGOHTUHKNQPRDY-UHFFFAOYSA-N CCCC(C(C=CC(Br)=C1)=C1C1=NN=NN1C)O Chemical compound CCCC(C(C=CC(Br)=C1)=C1C1=NN=NN1C)O PGOHTUHKNQPRDY-UHFFFAOYSA-N 0.000 claims description 2
- MKLFTRNSAKTBBN-UHFFFAOYSA-N CCCC(C(C=CC(Cl)=C1)=C1C1=NN=NN1C)O Chemical compound CCCC(C(C=CC(Cl)=C1)=C1C1=NN=NN1C)O MKLFTRNSAKTBBN-UHFFFAOYSA-N 0.000 claims description 2
- RSKDQFPDQQAEQE-UHFFFAOYSA-N CCCC(C(C=CC(F)=C1)=C1C1=NN=NN1C)O Chemical compound CCCC(C(C=CC(F)=C1)=C1C1=NN=NN1C)O RSKDQFPDQQAEQE-UHFFFAOYSA-N 0.000 claims description 2
- DKPNWSRAYNAVHH-UHFFFAOYSA-N CCCC(C(C=CC=C1)=C1C1=NN=NN1C)O Chemical compound CCCC(C(C=CC=C1)=C1C1=NN=NN1C)O DKPNWSRAYNAVHH-UHFFFAOYSA-N 0.000 claims description 2
- VBBOABPIHCLFAG-UHFFFAOYSA-N CCCCC(C(C=C(C=C1)Br)=C1C1=NN=NN1)O Chemical compound CCCCC(C(C=C(C=C1)Br)=C1C1=NN=NN1)O VBBOABPIHCLFAG-UHFFFAOYSA-N 0.000 claims description 2
- MYFVCWVTMHEDEM-UHFFFAOYSA-N CCCCC(C(C=CC=C1)=C1C1=NN=NN1C)O Chemical compound CCCCC(C(C=CC=C1)=C1C1=NN=NN1C)O MYFVCWVTMHEDEM-UHFFFAOYSA-N 0.000 claims description 2
- WKVAUFAOQDDQPP-UHFFFAOYSA-N CCCCC(C1=CC=CN=C1C1=NN=NN1)O Chemical compound CCCCC(C1=CC=CN=C1C1=NN=NN1)O WKVAUFAOQDDQPP-UHFFFAOYSA-N 0.000 claims description 2
- QBYABDIZRUWXKI-UHFFFAOYSA-N CCCCCC(C(C=C(C=C1)Br)=C1C1=NN=NN1)O Chemical compound CCCCCC(C(C=C(C=C1)Br)=C1C1=NN=NN1)O QBYABDIZRUWXKI-UHFFFAOYSA-N 0.000 claims description 2
- FPHAFXYTBFWFER-UHFFFAOYSA-N CCCCCC(C(C=CC(Br)=C1)=C1C1=NN=NN1C)O Chemical compound CCCCCC(C(C=CC(Br)=C1)=C1C1=NN=NN1C)O FPHAFXYTBFWFER-UHFFFAOYSA-N 0.000 claims description 2
- HXCUKFWXIWVQCC-UHFFFAOYSA-N CCCCCC(C(C=CC(Cl)=C1)=C1C1=NN=NN1C)O Chemical compound CCCCCC(C(C=CC(Cl)=C1)=C1C1=NN=NN1C)O HXCUKFWXIWVQCC-UHFFFAOYSA-N 0.000 claims description 2
- WGJSDVGUNDLRHR-UHFFFAOYSA-N CCCCCC(C(C=CC(F)=C1)=C1C1=NN=NN1C)O Chemical compound CCCCCC(C(C=CC(F)=C1)=C1C1=NN=NN1C)O WGJSDVGUNDLRHR-UHFFFAOYSA-N 0.000 claims description 2
- IQNOBXVLNRTHBR-UHFFFAOYSA-N CCCCCC(C(C=CC=C1)=C1C1=NN=NN1C)O Chemical compound CCCCCC(C(C=CC=C1)=C1C1=NN=NN1C)O IQNOBXVLNRTHBR-UHFFFAOYSA-N 0.000 claims description 2
- BMCUQLBCYLGCEX-UHFFFAOYSA-N CN1N=NN=C1C1=C(C=CC(=C1)C(F)(F)F)C(CCCC)O Chemical compound CN1N=NN=C1C1=C(C=CC(=C1)C(F)(F)F)C(CCCC)O BMCUQLBCYLGCEX-UHFFFAOYSA-N 0.000 claims description 2
- KAPXTXTUVJDEKR-UHFFFAOYSA-N CN1N=NN=C1C1=NC=CC=C1C(CCCC)O Chemical compound CN1N=NN=C1C1=NC=CC=C1C(CCCC)O KAPXTXTUVJDEKR-UHFFFAOYSA-N 0.000 claims description 2
- KYJOJHODOLNNEL-UHFFFAOYSA-N ClC1=CC(=C(C=C1)C(CCCC)O)C1=NN=NN1C Chemical compound ClC1=CC(=C(C=C1)C(CCCC)O)C1=NN=NN1C KYJOJHODOLNNEL-UHFFFAOYSA-N 0.000 claims description 2
- DZTFERBMFDTWGF-UHFFFAOYSA-N ClC1=CC=C(C(=N1)C1=NN=NN1)C(CCCC)O Chemical compound ClC1=CC=C(C(=N1)C1=NN=NN1)C(CCCC)O DZTFERBMFDTWGF-UHFFFAOYSA-N 0.000 claims description 2
- LINLJLFZCUEIEM-UHFFFAOYSA-N ClC1=CC=C(C(=N1)C1=NN=NN1C)C(CCCC)O Chemical compound ClC1=CC=C(C(=N1)C1=NN=NN1C)C(CCCC)O LINLJLFZCUEIEM-UHFFFAOYSA-N 0.000 claims description 2
- MDRHAIDMEDTCFT-UHFFFAOYSA-N FC1=CC(=C(C=C1)C(CCCC)O)C1=NN=NN1C Chemical compound FC1=CC(=C(C=C1)C(CCCC)O)C1=NN=NN1C MDRHAIDMEDTCFT-UHFFFAOYSA-N 0.000 claims description 2
- YJHGFPWXYOJICZ-UHFFFAOYSA-N FC1=CC=C(C(=N1)C1=NN=NN1)C(CCCC)O Chemical compound FC1=CC=C(C(=N1)C1=NN=NN1)C(CCCC)O YJHGFPWXYOJICZ-UHFFFAOYSA-N 0.000 claims description 2
- XNMCWXOWIPTFKU-UHFFFAOYSA-N FC1=CC=C(C(=N1)C1=NN=NN1C)C(CCCC)O Chemical compound FC1=CC=C(C(=N1)C1=NN=NN1C)C(CCCC)O XNMCWXOWIPTFKU-UHFFFAOYSA-N 0.000 claims description 2
- NIRSUCLTRSKBPB-UHFFFAOYSA-N N1N=NN=C1C1=C(C=CC(=C1)C(F)(F)F)C(CCCC)O Chemical compound N1N=NN=C1C1=C(C=CC(=C1)C(F)(F)F)C(CCCC)O NIRSUCLTRSKBPB-UHFFFAOYSA-N 0.000 claims description 2
- NAEWIZJBPAIJHQ-UHFFFAOYSA-N NC1=CC(=C(C=C1)C(CCCC)O)C1=NN=NN1 Chemical compound NC1=CC(=C(C=C1)C(CCCC)O)C1=NN=NN1 NAEWIZJBPAIJHQ-UHFFFAOYSA-N 0.000 claims description 2
- STPJMXFYVPLHHZ-UHFFFAOYSA-N NC1=CC(=C(C=C1)C(CCCC)O)C1=NN=NN1C Chemical compound NC1=CC(=C(C=C1)C(CCCC)O)C1=NN=NN1C STPJMXFYVPLHHZ-UHFFFAOYSA-N 0.000 claims description 2
- OHFUSFWCFQLAQD-UHFFFAOYSA-N [N+](=O)([O-])C1=CC(=C(C=C1)C(CCCC)O)C1=NN=NN1 Chemical compound [N+](=O)([O-])C1=CC(=C(C=C1)C(CCCC)O)C1=NN=NN1 OHFUSFWCFQLAQD-UHFFFAOYSA-N 0.000 claims description 2
- NURFAOPTNYXODN-UHFFFAOYSA-N [N+](=O)([O-])C1=CC(=C(C=C1)C(CCCC)O)C1=NN=NN1C Chemical compound [N+](=O)([O-])C1=CC(=C(C=C1)C(CCCC)O)C1=NN=NN1C NURFAOPTNYXODN-UHFFFAOYSA-N 0.000 claims description 2
- 230000002152 alkylating effect Effects 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- ZXPSRPAUXQIYID-UHFFFAOYSA-N [N].[Na] Chemical compound [N].[Na] ZXPSRPAUXQIYID-UHFFFAOYSA-N 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 24
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 20
- 241000700159 Rattus Species 0.000 abstract description 13
- 238000002474 experimental method Methods 0.000 abstract description 12
- 208000006011 Stroke Diseases 0.000 abstract description 7
- 238000010171 animal model Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 230000001605 fetal effect Effects 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 210000003618 cortical neuron Anatomy 0.000 abstract description 5
- 206010029260 Neuroblastoma Diseases 0.000 abstract description 4
- 206010008118 cerebral infarction Diseases 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 4
- 239000004090 neuroprotective agent Substances 0.000 abstract description 4
- 201000006474 Brain Ischemia Diseases 0.000 abstract description 3
- 206010008089 Cerebral artery occlusion Diseases 0.000 abstract description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract description 3
- 230000002490 cerebral effect Effects 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 3
- 201000007309 middle cerebral artery infarction Diseases 0.000 abstract description 3
- 230000001052 transient effect Effects 0.000 abstract description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 3
- 238000010276 construction Methods 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 description 97
- 230000015572 biosynthetic process Effects 0.000 description 65
- 238000003786 synthesis reaction Methods 0.000 description 65
- HJXMNVQARNZTEE-UHFFFAOYSA-N Butylphthalide Chemical compound C1=CC=C2C(CCCC)OC(=O)C2=C1 HJXMNVQARNZTEE-UHFFFAOYSA-N 0.000 description 25
- 239000002994 raw material Substances 0.000 description 19
- 239000007787 solid Substances 0.000 description 18
- 239000002609 medium Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000001681 protective effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 229950005197 butylphthalide Drugs 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical group ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- YZWKKMVJZFACSU-UHFFFAOYSA-N 1-bromopentane Chemical compound CCCCCBr YZWKKMVJZFACSU-UHFFFAOYSA-N 0.000 description 4
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 4
- 208000032382 Ischaemic stroke Diseases 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- LXEKPEMOWBOYRF-UHFFFAOYSA-N [2-[(1-azaniumyl-1-imino-2-methylpropan-2-yl)diazenyl]-2-methylpropanimidoyl]azanium;dichloride Chemical compound Cl.Cl.NC(=N)C(C)(C)N=NC(C)(C)C(N)=N LXEKPEMOWBOYRF-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229960004676 antithrombotic agent Drugs 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 229940127218 antiplatelet drug Drugs 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical group [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- IBRODYNXELBTJC-UHFFFAOYSA-N 5-fluoro-2-methylbenzonitrile Chemical compound CC1=CC=C(F)C=C1C#N IBRODYNXELBTJC-UHFFFAOYSA-N 0.000 description 2
- 239000012583 B-27 Supplement Substances 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 239000007875 V-40 Substances 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001335 aliphatic alkanes Chemical group 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 230000000320 anti-stroke effect Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OCKPCBLVNKHBMX-UHFFFAOYSA-N butylbenzene Chemical compound CCCCC1=CC=CC=C1 OCKPCBLVNKHBMX-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001120 cytoprotective effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000004807 desolvation Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910001389 inorganic alkali salt Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960003088 loratadine Drugs 0.000 description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000007473 univariate analysis Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- YJNHLGKBKBWMNT-UHFFFAOYSA-N 2-chloro-6-formylbenzonitrile Chemical compound ClC1=CC=CC(C=O)=C1C#N YJNHLGKBKBWMNT-UHFFFAOYSA-N 0.000 description 1
- QVTPWONEVZJCCS-UHFFFAOYSA-N 2-formylbenzonitrile Chemical compound O=CC1=CC=CC=C1C#N QVTPWONEVZJCCS-UHFFFAOYSA-N 0.000 description 1
- NKYUMNAHEJWIND-UHFFFAOYSA-N 2-methyl-5-(trifluoromethyl)benzonitrile Chemical compound CC1=CC=C(C(F)(F)F)C=C1C#N NKYUMNAHEJWIND-UHFFFAOYSA-N 0.000 description 1
- XOSDYLFXPMFRGF-UHFFFAOYSA-N 2-methyl-5-nitrobenzonitrile Chemical compound CC1=CC=C([N+]([O-])=O)C=C1C#N XOSDYLFXPMFRGF-UHFFFAOYSA-N 0.000 description 1
- WNVUTFDOGUGEIS-UHFFFAOYSA-N 5-bromo-2-methylbenzonitrile Chemical compound CC1=CC=C(Br)C=C1C#N WNVUTFDOGUGEIS-UHFFFAOYSA-N 0.000 description 1
- HFBZPKYQUFLCEL-UHFFFAOYSA-N 5-chloro-2-methylbenzonitrile Chemical compound CC1=CC=C(Cl)C=C1C#N HFBZPKYQUFLCEL-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- UGYACEKSWPFVLB-UHFFFAOYSA-N BrC1=CC(=C(C=C1)C(CCCC)O)C1=NN=NN1.[K] Chemical compound BrC1=CC(=C(C=C1)C(CCCC)O)C1=NN=NN1.[K] UGYACEKSWPFVLB-UHFFFAOYSA-N 0.000 description 1
- UHFPVRVZEXVUQX-UHFFFAOYSA-N BrC1=CC=C(C(=N1)C1=NN=NN1)C(CCCC)O.[K] Chemical compound BrC1=CC=C(C(=N1)C1=NN=NN1)C(CCCC)O.[K] UHFPVRVZEXVUQX-UHFFFAOYSA-N 0.000 description 1
- SPMQNMLQQZOZHG-UHFFFAOYSA-N BrC1=CC=C(C(=N1)C1=NN=NN1)C(CCCC)O.[Li] Chemical compound BrC1=CC=C(C(=N1)C1=NN=NN1)C(CCCC)O.[Li] SPMQNMLQQZOZHG-UHFFFAOYSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- VBBOABPIHCLFAG-NSHDSACASA-N CCCC[C@@H](C(C=C(C=C1)Br)=C1C1=NN=NN1)O Chemical compound CCCC[C@@H](C(C=C(C=C1)Br)=C1C1=NN=NN1)O VBBOABPIHCLFAG-NSHDSACASA-N 0.000 description 1
- QBVFJSYWFVRUFG-NSHDSACASA-N CCCC[C@@H](C(C=CC(Br)=C1)=C1C1=NN=NN1)O Chemical compound CCCC[C@@H](C(C=CC(Br)=C1)=C1C1=NN=NN1)O QBVFJSYWFVRUFG-NSHDSACASA-N 0.000 description 1
- DTTARXDGGBQTNS-NSHDSACASA-N CCCC[C@@H](C(C=CC(Cl)=C1)=C1C1=NN=NN1)O Chemical compound CCCC[C@@H](C(C=CC(Cl)=C1)=C1C1=NN=NN1)O DTTARXDGGBQTNS-NSHDSACASA-N 0.000 description 1
- ULMDNBFPIYUJDA-NSHDSACASA-N CCCC[C@@H](C(C=CC(F)=C1)=C1C1=NN=NN1)O Chemical compound CCCC[C@@H](C(C=CC(F)=C1)=C1C1=NN=NN1)O ULMDNBFPIYUJDA-NSHDSACASA-N 0.000 description 1
- VBBOABPIHCLFAG-LLVKDONJSA-N CCCC[C@H](C(C=C(C=C1)Br)=C1C1=NN=NN1)O Chemical compound CCCC[C@H](C(C=C(C=C1)Br)=C1C1=NN=NN1)O VBBOABPIHCLFAG-LLVKDONJSA-N 0.000 description 1
- QBVFJSYWFVRUFG-LLVKDONJSA-N CCCC[C@H](C(C=CC(Br)=C1)=C1C1=NN=NN1)O Chemical compound CCCC[C@H](C(C=CC(Br)=C1)=C1C1=NN=NN1)O QBVFJSYWFVRUFG-LLVKDONJSA-N 0.000 description 1
- DTTARXDGGBQTNS-LLVKDONJSA-N CCCC[C@H](C(C=CC(Cl)=C1)=C1C1=NN=NN1)O Chemical compound CCCC[C@H](C(C=CC(Cl)=C1)=C1C1=NN=NN1)O DTTARXDGGBQTNS-LLVKDONJSA-N 0.000 description 1
- ULMDNBFPIYUJDA-LLVKDONJSA-N CCCC[C@H](C(C=CC(F)=C1)=C1C1=NN=NN1)O Chemical compound CCCC[C@H](C(C=CC(F)=C1)=C1C1=NN=NN1)O ULMDNBFPIYUJDA-LLVKDONJSA-N 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- FQEGCTURFABAPM-UHFFFAOYSA-N [Na].BrC1=CC=C(C(=N1)C1=NN=NN1)C(CCCC)O Chemical compound [Na].BrC1=CC=C(C(=N1)C1=NN=NN1)C(CCCC)O FQEGCTURFABAPM-UHFFFAOYSA-N 0.000 description 1
- XLIJUKVKOIMPKW-BTVCFUMJSA-N [O].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O Chemical compound [O].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XLIJUKVKOIMPKW-BTVCFUMJSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
- 229950009041 edaravone Drugs 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- KIMZVDLDHKECSU-UHFFFAOYSA-N imidazo[1,2-a]pyridine-3-carbaldehyde Chemical compound C1=CC=CN2C(C=O)=CN=C21 KIMZVDLDHKECSU-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960001148 rivaroxaban Drugs 0.000 description 1
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000011631 stroke animal model Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the invention relates to the field of medicine, in particular to tetrazolium derivatives, preparation methods, pharmaceutical compositions containing them and their use in the preparation of medicines for preventing and fighting cardiovascular and cerebrovascular diseases, improving cardiovascular and cerebrovascular circulatory disorders or antithrombotics application.
- Stroke is one of the common cardiovascular and cerebrovascular diseases, and has become the leading cause of disability and the second leading cause of death in adults worldwide.
- the incidence of ischemic stroke accounts for about 80% of the total stroke, which seriously threatens human health.
- research has focused on finding more effective treatment strategies to reduce stroke-related death and disability.
- a variety of drugs have been explored in clinical experiments and animal models, but effective therapeutic strategies are still lacking.
- neuroprotective agent for the prevention of acute ischemic stroke so new compounds with new structural characteristics and new mechanisms of action are needed, and this field has a broad market and clinical needs.
- Tetrazolium derivatives have a wide range of applications in drug development, and have shown good efficacy in anti-hypertension, anti-inflammatory, antibacterial, platelet aggregation inhibitors and asthma treatment, such as antihypertensive drugs - the first Losartan, a potent orally active non-peptide angiotensin II receptor antagonist, and cilostazol, a platelet aggregation inhibitor, have introduced a tetrazolium structure and achieved very good pharmacological results. Effect.
- the object of the present invention is to provide a tetrazolium derivative and a pharmaceutically acceptable salt or solvate thereof.
- the present invention also provides a method for preparing the above-mentioned tetrazolium derivatives.
- the present invention also provides a pharmaceutical composition containing the above-mentioned tetrazolium derivatives and their pharmaceutically acceptable salts or solvates.
- the present invention also provides a use of the above-mentioned tetrazolium derivatives and their pharmaceutically acceptable salts or solvates for preparing medicines for preventing and fighting stroke.
- the present invention adopts the following technical scheme:
- the present invention provides a kind of tetrazolium derivatives, it is characterized in that, has the structure shown in general formula (I):
- R 1 is H, C 1 -C 3 alkyl chain or haloalkyl chain
- R 2 is H, amino, nitro, hydroxyl, ether bond, methyl, ester, carbonyl, -CF 3 , -OCF 3 , n-butyl, isopropyl, peptide bond, one or more Cl, one or F, one or more Br, or a combination of at least two of one or more Cl, one or more F, and one or more Br;
- R3 is independently selected from
- A is a benzene ring or a six-membered heterocyclic ring containing at least one N atom or a five-membered heterocyclic ring containing at least one N atom.
- R 1 is H and A is a benzene ring
- R 2 is not H, F, Cl, or Br
- the tetrazolium derivatives of the present invention have the structure shown in the general formula (II):
- R 1 , R 2 and R 3 are as defined above; X is C or N.
- tetrazolium derivatives have the structure shown in general formula III:
- R 1 is H, methyl, ethyl
- R 2 is H, Cl, F, Br or amino
- X is C or N.
- the R 1 is methyl, ethyl; preferably, the X is N;
- the pharmaceutically acceptable salt thereof is preferably one with sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium methoxide, potassium methoxide, sodium ethoxide, potassium ethoxide, triethylamine, tert-butylamine one or more constituent salts;
- the tetrazolium derivatives include one or more of the following compounds:
- the preferred compounds of the present invention are:
- the pharmaceutically acceptable salt is a salt formed with one or more of the following bases: sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium methoxide, potassium methoxide, sodium ethoxide, potassium ethoxide , triethylamine, tert-butylamine.
- the tetrazolium derivatives include:
- the tetrazolium derivatives include:
- a method for preparing a tetrazolium derivative the compound (1) is reacted with an acyl protective reagent to obtain a compound (2), the compound (2) is reacted with sodium azide, and then hydrochloric acid is added to simultaneously remove the protective group and eliminate the remaining sodium azide to obtain compound (3), and compound (3) can be reacted with Grignard reagent to obtain the compound shown in formula (I); optionally, the compound shown in formula (I) can be combined with The alkylation reagent is reacted to obtain a tetrazolium alkyl substitution to produce a compound represented by the formula (I'):
- the acyl protecting reagent is ethylene glycol.
- the compound (1) can be obtained from the compound described in the formula (1-1) through bromination and hydrolysis:
- NBS is used as the brominating reagent
- AIBN as an initiator
- the reaction solvent is carbon tetrachloride
- the reaction temperature is the reflux temperature
- the reaction time is 10 to 24 hours .
- the molar ratio of the brominated reagent to the compound (1-1) is 1.5-3:1.
- water and ethanol (1:1) and the same equivalent of silver nitrate as the compound are directly added to carry out the hydrolysis reaction of the second step, and the reaction temperature is 60-80° C.
- the reaction time was 4 hours.
- the temperature at which the compound (1) reacts with the acyl protecting reagent is 70-130° C.; the reaction reagent can be selected from toluene, and the catalyst can be selected from p-toluenesulfonic acid.
- the molar ratio of ethylene glycol to compound (1) is 1 to 10:1, more preferably 2 to 8:1, and still more preferably 4 to 7:1.
- the molar ratio of p-toluenesulfonic acid to compound (1) is 0.03 to 0.2:1, more preferably 0.05 to 0.1:1.
- the reaction temperature of the compound (2) with sodium azide is 110-170°C.
- Ammonium chloride was added, the reaction solvent was DMF, and after the reaction was completed, dilute hydrochloric acid was used for quenching.
- the molar ratio of the sodium azide to the compound (2) is 2-10:1, more preferably 4-7:1.
- the molar ratio of ammonium chloride to compound (2) is 2 to 10:1, more preferably 4 to 7:1.
- the Grignard reagent can be a commercially available product or can be prepared on site. It can be obtained by reacting brominated C 3 -C 5 alkanes with magnesium. During the preparation process, iodine particles can be added.
- the molar ratio of the brominated C 3 -C 5 alkane to compound (2) is 2-10:1, more preferably 4-7:1.
- the reaction temperature of the compound (3) and the alkylating reagent (iodine) is 30-50° C.
- the reaction solvent is DMF
- the catalyst is sodium hydrogen.
- the molar ratio of the iodohydrocarbon to the compound (3) is 1 to 2:1, more preferably 1 to 1.5:1.
- the molar ratio of sodium hydrogen to compound (3) is 2 to 3:1, more preferably 2.5 to 3:1.
- a pharmaceutical composition comprising at least one active component and one or more pharmaceutically acceptable carriers or excipients, wherein the active component is described in any of the above-mentioned technical solutions tetrazolium derivatives.
- pharmaceutically acceptable derivatives refers to salts and solvates of the selected compound.
- alkyl refers to a straight or branched chain alkane group containing carbon atoms
- examples of “alkyl” as used herein include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, etc.
- alkane “Radical” also includes substituted alkyl groups.
- the alkyl group can be optionally substituted one or more times with halogen.
- halogen as used herein means fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine.
- solvate refers to a complex of variable stoichiometry formed by a solute (eg: general formula (I) of the present invention) and a solvent.
- the solvent must not interfere with the biological activity of the solute.
- suitable solvents include, but are not limited to, water, methanol, ethanol, and acetic acid.
- Preferred solvents for use are pharmaceutically acceptable solvents.
- Suitable pharmaceutically acceptable solvents include, but are not limited to, water, ethanol and acetic acid. More preferably, the solvent used is water.
- the salts of the tetrazolium compounds described in the present invention can be prepared by methods well known to those skilled in the art.
- the salts can be organic alkali salts, inorganic alkali salts, etc.
- the organic alkali salts include sodium methoxide, potassium methoxide, sodium ethoxide, potassium ethoxide, triethylamine, tert-butylamine, etc.
- the inorganic alkali salts include hydroxide Sodium, Potassium Hydroxide, Lithium Hydroxide, etc.
- the second object of the present invention is to provide a pharmaceutical composition
- a pharmaceutical composition comprising at least one active ingredient and one or more pharmaceutically acceptable carriers or excipients, the active ingredient It can be the tetrazolium compound of the structure represented by the general formula (I) of the present invention and its preferred compound, the optical isomer of the compound, the pharmaceutically acceptable salt of the compound or its optical isomer, the any one or more of the solvates of the compounds or their optical isomers.
- the carrier includes one or more of conventional diluents, excipients, fillers, binders, wetting agents, disintegrating agents, absorption enhancers, surfactants, adsorption carriers, lubricants, etc. in the pharmaceutical field , and if necessary, flavoring agents, sweeteners, etc. can be added.
- the medicine of the present invention can be made into various forms such as tablets, powders, granules, capsules, oral liquids and injections, and the medicines of the above-mentioned dosage forms can be prepared according to conventional methods in the pharmaceutical field.
- the present invention also provides the compound described in (I), and its optical isomer or its pharmaceutically acceptable salt or solvate in the preparation of preventing and combating cardiovascular and cerebrovascular diseases, improving cardiovascular and cerebrovascular circulatory disorders, or preventing and resisting cardiovascular and cerebrovascular diseases. Use in the medicament of thrombosis.
- the present invention also provides the use of the compound of the present invention or a pharmaceutically acceptable salt thereof in the preparation of medicines for preventing and combating cardiovascular and cerebrovascular diseases, improving cardiovascular and cerebrovascular circulation disorders, or antithrombotics, especially in the preparation of medicines for the treatment of acute deficiency Application of hemorrhagic stroke.
- the present invention provides the application of tetrazolium compounds or their pharmaceutically acceptable salts alone or in combination with other drugs in the treatment of acute ischemic stroke.
- anti-stroke drugs that can be used in combination with the compounds provided by the present invention or their pharmaceutically acceptable salts include, but are not limited to, at least one of the following categories: free radical scavengers (such as Edaravone); neuroprotective agents (such as Spritz) ; Antiplatelet drugs (eg, clopidogrel, aspirin); Antithrombotic drugs (eg, rivaroxaban).
- free radical scavengers such as Edaravone
- neuroprotective agents such as Spritz
- Antiplatelet drugs eg, clopidogrel, aspirin
- Antithrombotic drugs eg, rivaroxaban.
- the inventors of the present invention have confirmed through multiple experiments that the compounds of the present invention have inhibitory activity on ADP-induced platelet aggregation and good oral pharmacokinetic properties in rats. Therefore, the compounds of the present invention can be used as neuroprotective agents in the preparation of medicines for the treatment and prevention of acute ischemic stroke.
- Figure 1 The structure of positive drug butylphthalide (NBP) and BZP;
- Fig. 2 The protective effect of compounds on primary cortical neurons of fetal rat modeled by OGD/R;
- Figure 4 The pharmacodynamic effects of compounds in the establishment of focal cerebral ischemia animal model with transient middle cerebral artery occlusion by online embolization; #p ⁇ 0.05, ##p ⁇ 0.01, ###p ⁇ 0.001versus vehicle group;* p ⁇ 0.05versus NBP group. Error bars, SEM.
- Step 1 Add Intermediate 1-3 (2.8g, 20mmol), ethylene glycol (6.2g, 0.1mol), toluene (20ml), p-toluenesulfonic acid (275mg, 1.6mmol) to a single-necked flask and heat to reflux, Use the water separator to separate the water until the water volume in the water separator no longer increases, and cool to room temperature. Saturated sodium bicarbonate solution was added until the aqueous layer was neutral or basic, the aqueous layer was separated, and the organic layer was concentrated under reduced pressure to obtain 4.5 g of light yellow oily semisolid intermediate 1-4. Yield 89%. The purity is greater than 99%.
- intermediate 9-3 was used to replace intermediate 1-3
- intermediate 9-4 was used to replace intermediate 1-4 to obtain 3.5 g of solid 9-5 with a yield of 69% (two step), purity greater than 99%
- intermediate 10-3 was used to replace intermediate 1-3
- intermediate 10-4 was used to replace intermediate 1-4 to obtain 2.7 g of solid 10-5 with a yield of 64% (two step), purity greater than 99%
- bromobutane (688.84mg, 5.03mmol), iodine pellets (100mg, 0.39mmol), metal magnesium bars (100.56mg, 4.19mmol), 10ml of anhydrous tetrahydrofuran, nitrogen protection, heating under reflux for 12h, in Dissolve 189 mg of intermediate 1-5 in 15 mL of anhydrous tetrahydrofuran in a three-necked flask, under nitrogen protection, inject the prepared Grignard reagent under ice bath conditions, and react at room temperature for 10 h.
- V-7 was used instead of V-1 to obtain 30 mg of the target compound V-8 with a purity of more than 99%.
- 1 HNMR (CD 3 OD, 500 MHz) ⁇ : 0.71 (t, 3H, CH 3 ), 0.83-1.25 (m, 6H, CH 2 ), 3.95 (s, 3H, N-CH 3 ), 4.67 (t, 1H, C(OH)H), 7.69 (d, 1H, ArH), 8.13 (d, 1H, ArH).
- HRMS m/z (ESI) calcd for C12H16BrN5O [M+H] + 326.05 found: 325.69 .
- Example 66 Inhibitory effect of the disclosed compounds on ADP-induced platelet aggregation in vitro
- the washed platelet sample without any reagents or drugs was used as blank control group, the washed platelet sample administered with ADP and dimethyl sulfoxide (DMSO) was used as negative control, and the washed platelet sample administered with ADP and the listed drug butylphthalide (NBP) was used as the negative control. Platelet samples were positive controls.
- the inhibitory effect of the compounds obtained in the present invention on ADP-induced platelet aggregation was determined using an in vitro platelet aggregation assay.
- Test drug the monomer compound obtained by the present invention.
- Positive control drug Butylphthalide was purchased from Shanghai Bide Pharmaceutical Technology Co., Ltd. Purity >95%.
- Experimental animals SPF grade SD male rats. Raised in stainless steel wire cages with a volume of 500 ⁇ 350 ⁇ 200 mm (length ⁇ width ⁇ height), with no more than 5 per cage. During the experiment, animals of other species shall not be kept in the same room area. Laboratory animal license number: SYXK (Zhe) 2012-0178. The temperature is strictly controlled at 18-26°C, the humidity is 40%-70%, the daily temperature difference does not exceed 4°C, the ventilation frequency is > 8 times/hour, and the light is controlled for 12 hours/dark for 12 hours. Day and night (8:00-20: 00 light). The experimental animals were given free access to water and food using drinking bottles.
- the method for obtaining the washed platelet samples SD rats were anesthetized by intraperitoneal injection of 10% chloral hydrate with 0.3ml/100g, and blood was collected from the abdominal aorta. agent (ACD) in a centrifuge tube. Mix by blood:ACD volume 9:1. Centrifuge at 120 g for 20 min at 25°C to obtain the supernatant, platelet rich plasma (PRP). The PRP was diluted with ACD to prepare washed platelets, and the blood: ACD volume was mixed at 1:3, 800 g; centrifuged at 25°C for 10 min to obtain the platelets.
- ACD abdominal aorta. agent
- In vitro platelet aggregation experiment blank control group: take the washed platelet sample (290 ⁇ L) and incubate at room temperature for 3 min in a disposable sample cup equipped with a disposable stirrer, then put it into the incubation hole of the Prism four-channel platelet aggregation tester and incubate at 37 °C 3min, after zeroing with PPP, adding inducer ADP 10 ⁇ L (ADP system concentration is 10uM, blank control group adding 10 ⁇ l normal saline) to detect platelet aggregation rate, record the maximum platelet aggregation rate (%) within 300s. The platelet aggregation-inducing effect of ADP was confirmed.
- Negative control group Wash the platelet sample (288 ⁇ l) in a disposable sample cup equipped with a disposable stirrer, add 2 ⁇ L DMSO, incubate at room temperature for 3 minutes, and then put it into the incubation hole of the Prism four-channel platelet aggregation tester and incubate at 37°C 3min, after zeroing with PPP, adding inducer ADP 10 ⁇ L (the concentration of ADP system is 10uM) to detect the platelet aggregation rate, and record the maximum platelet aggregation rate (%) within 300s. Each group is paralleled three times.
- Positive control group and experimental group Take the washed platelet sample (288 ⁇ l) in a disposable sample cup equipped with a disposable stirrer, add 2 ⁇ L of butylphthalide or the compound obtained by the present invention (the system concentration of the compound is 0.1 mM), and incubate at room temperature for 3 min , and then put it into the incubation hole of the Prism four-channel platelet aggregation tester for 3 minutes at 37°C. After zeroing with PPP, add 10 ⁇ L of the inducer ADP (the concentration of the ADP system is 10 uM) to detect the platelet aggregation rate, and record the maximum platelet aggregation within 300s. Rate(%). Each group is paralleled three times. Inhibition rate calculation formula:
- +++ indicates that the inhibition rate value is greater than 30%
- N.S. means the value is less than 10%.
- Example 67 Protective effect of compounds disclosed in the present invention on primary cortical neurons of OGD/R fetuses
- the normal neuron cells without OGD/R modeling were used as the control group, and the neuronal cells only with OGD/R modeling without drug treatment were used as the model group. OGD/R modeling was performed and the listed drug butylbenzene was used.
- the neuronal cells treated with phthalein (NBP) and BZP are the positive controls, and the neuronal cells treated with the compound of the present invention are used for OGD/R modeling as the experimental group. cytoprotective effects of fetal rat primary cortical neurons.
- the pharmacological experimental method of the neuron cytoprotective effect of the OGD/R model of the compound of the present invention is as follows:
- Test drug the monomer compound obtained by the present invention.
- Positive control drugs butylphthalide and BZP were purchased from Shanghai Bide Pharmaceutical Technology Co., Ltd. Purity >95%.
- Cell line day 15 ICR fetal rat cerebral cortex neurons.
- NB medium Neurobasal (NB medium), B27 additive, GlutaMax additive, DMEM sugar-free, FBS, produced by Gibco Company in the United States.
- NBM/B27 medium - low glutamine version if using a 50mL centrifuge tube, add 45mL NB medium, 0.9mL B27 supplement, 1% double antibody, 11.25 ⁇ L Glutamax supplement;
- NBM/B27 medium-high glutamine version if using a 50mL centrifuge tube, add 45mL NB medium, 0.9mL B27 supplement, 1% double antibody, 27 ⁇ L Glutamax supplement;
- Drug preparation method Dissolve the drug in DMSO to prepare a stock solution of the corresponding concentration, and dilute it with the medium according to a certain proportion.
- the pregnant mice were sacrificed by cervical dislocation, placed in a supine position, their abdomens were opened, and their uterus was taken.
- the obtained fetal rat was placed in HBSS, the brain was removed using surgical scissors and forceps, and the superficial vascular membrane was isolated.
- the obtained cells were incubated in a 37°C, 5% CO2 cell incubator, and the medium was changed in half every three days (NBM/B27 medium-low glutamine version), and the cells were administered 2 hours before OGD on the seventh day.
- ODG After 2 hours, the cell culture medium was replaced with sugar-free DMEM (placed in an anaerobic box for 20 minutes to remove O2, and washed three times), placed in an anaerobic box (95% N2+5% CO 2 ), and cultured at 37°C 2h.
- Determination of cell viability with CCK8 kit add 10 boxes of cell viability assay solution to each well, incubate in a 37°C, 5% CO 2 cell incubator for 2 h, and measure the absorbance of each well at 450 nm.
- cell viability % (OD value of drug group - OD value of blank well background)/(cell OD value of control group - OD value of blank well background) D background.
- the target compound group had higher cell viability compared with the NBP group and BZP.
- the V-9a-1 ⁇ M group and the NBP-10 ⁇ M group and the BZP-10 ⁇ M group there is no significant difference between the V-9a-1 ⁇ M group and the NBP-10 ⁇ M group and the BZP-10 ⁇ M group; however, there is a significant difference between the 10 ⁇ M group of the compound of the present invention and the NBP-10 ⁇ M and BZP-10 ⁇ M groups, which is significantly higher than that of the NBP-10 ⁇ M group.
- BZP-10 ⁇ M group it can be considered that the compound of the present invention exhibits a higher neuroprotective effect at a low concentration.
- Example 68 Protective effect of compounds disclosed in the present invention on neuroblastoma cells (N2A) OGD/R injury
- Neuroblastoma cells were induced to differentiate into neuron-like cells before OGD/R modeling. After 4 hours of oxygen-glucose deprivation, DMEM medium containing serum sugar was added to achieve reperfusion, and the cells at 24 h after reperfusion were subjected to subsequent analysis. The experiment was divided into 8 groups: Control group, model group, positive drug NBP-10 ⁇ M group, V-9a 0.1 ⁇ M group, V-9a 1 ⁇ M group, V-9a 10 ⁇ M group, V-9a 100 ⁇ M group. The corresponding drugs in each group were added to the cell culture medium during reperfusion.
- Sample collection 0.10 mL of blood was collected from each animal through the orbit each time, and EDTAK2 was anticoagulated. Blood samples were placed on ice after collection, and centrifuged within 30 minutes to separate plasma (centrifugation conditions: 5000 rpm, 10 minutes, 4°C). Store at -80°C until analysis.
- Liquid phase method Column: ACQUITY BEH C18 2.1x50mm 1.7 ⁇ m
- Mobile phase A 0.1% formic acid water
- mobile phase B acetonitrile
- flow rate 0.35 mL/min
- the mobile phase ratio changes over time:
- Mass spectrometry method capillary voltage: 3.5kV, desolvation gas temperature: 500°C, desolvation gas flow rate: 1000L/Hr, cone gas flow rate: 50L/Hr.
- Determination of plasma concentration take 50 ⁇ L of plasma sample, add 200 ⁇ L of acetonitrile (containing loratadine 1 ng/mL), vortex for 3 min, centrifuge at 20,000 rcf for 10 min at 4°C, and take the supernatant for LC-MS/MS analysis.
- the plasma concentration was calculated by the standard curve and Cmax (ug/L) and AUC 0-t (hr*ng/mL) were calculated by Das 2.0, as shown in Table 3.
- Example 70 Pharmacodynamic effects of the compounds disclosed in the present invention in stroke animal models
- the tetrazolium derivatives involved in the present invention have broad application prospects for preventing and combating cardiovascular and cerebrovascular diseases, improving cardiovascular and cerebrovascular circulation disorders or antithrombotics.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种四氮唑类衍生物,具有通式I所示的结构,本发明同时公开了含有上述四氮唑类衍生物的组合物以及其在制备预防和抗脑卒中中的应用。本发明发明人通过多次实验证实,本发明化合物对ADP诱导的血小板聚集活性有明显抑制作用,对于OGD/R胎鼠原代皮层神经元细胞和神经母细胞瘤细胞(N2A)诱导分化的神经元样细胞有突出的损伤保护作用,对于线栓法短暂性大脑中动脉阻塞构建局灶性脑缺血动物模型具有良好的抗脑卒中药效以及具有良好的大鼠口服药代动力学性质。因此,本发明化合物可作为神经保护剂应用于治疗和预防脑卒中的药物中。
Description
本发明涉及药物领域,具体涉及四氮唑类衍生物、制备方法、含其的药物组合物及其在制备预防和对抗心脑血管性疾病、改善心脑血管循环障碍或抗血栓的药物中的应用。
脑卒中是常见的心脑血管疾病之一,已成为全球成年人残疾的主要原因和第二大死亡因素。缺血性脑卒中发生率占总脑卒中的80%左右,严重威胁人类的健康。近十年来,研究主要集中在探索更加有效的治疗策略来减少中风引起的死亡以及残疾。多种药物在临床实验和动物模型中被探索,但是仍然缺乏有效的治疗策略。此外尚无针对急性缺血性脑卒中的神经保护剂预防用药,因此需要具有新的结构特征和新的作用机制的新型化合物,该领域具有着广阔的市场以及临床需求。四氮唑类衍生物在药物开发方面有着广泛的应用,在抗高血压,消炎,抗菌,血小板凝集抑制剂和哮喘的治疗等方面都表现出良好的药效,如降压类药物-第一个有口服活性的强效非肽类血管紧张素Ⅱ受体拮抗剂氯沙坦(Losartan),血小板凝集抑制剂类药物西洛他唑均引入了四氮唑类结构并取得了非常好的药理效果。
发明内容
本发明的目的是提供一种四氮唑类衍生物及其药学上可接受的盐或溶剂合物。
本发明还提供了一种制备上述四氮唑类衍生物的方法。
本发明同时提供了一种含有上述四氮唑类衍生物及其药学上可接受的盐或溶剂合物的药物组合物。
本发明还提供了一种利用上述四氮唑类衍生物及其药学上可接受的盐或溶剂合物制备预防和对抗脑卒中的药物中的应用。
本发明采用如下的技术方案:
本发明提供了一种四氮唑类衍生物,其特征在于,具有通式(I)所示的结构:
或其光学异构体;
或其药学上可接受的盐或溶剂合物;
其中:R
1为H,C
1-C
3的烷基链或卤代烷基链;
R
2为H,氨基,硝基,羟基,醚键,甲基,酯基,羰基,-CF
3,-OCF
3,正丁基,异丙基,肽键,一个或多个Cl,一个或多个F,一个或多个Br,或由一个或多个Cl、一个或多个F、一个或多个Br中至少两种形成的组合;
其中R
4为H或-C(=O)C
1-C
3烷基;
A为苯环或含有至少一个N原子的六元杂环或含有至少一个N原子的五元杂环。
作为优选,R
1为H且A为苯环时,R
2不为H、F、Cl、Br;
进一步地,作为优选,本发明四氮唑类衍生物具有通式(II)所示的结构:
或其光学异构体;或其药学上可接受的盐或溶剂合物;
其中,R
1、R
2、R
3定义同上;X为C或N。
进一步地,作为优选,所述的四氮唑类衍生物具有通式III所示的结构:
或其光学异构体;或其药学上可接受的盐或溶剂合物;或其光学异构体药学上可接受的盐或溶剂合物;
作为优选,R
1为H、甲基、乙基;R
2为H、Cl、F、Br或氨基;
X为C或N。
作为优选,所述R
1为甲基、乙基;作为优选,所述X为N;
进一步地,作为优选,所述的其药学上可接受的盐优选为与氢氧化钠,氢氧化钾,氢氧化锂,甲醇钠,甲醇钾,乙醇钠,乙醇钾,三乙胺,叔丁胺中一种或多种构成的盐;
更进一步优选为氢氧化钠,氢氧化钾的通式Va、Vb结构:
或其光学异构体,其中,X,R
2定义同上。
作为优选,所述的四氮唑类衍生物包括如下化合物中的一种或多种:
1-(4-溴-2-(1-甲基-1H-四唑-5-基)苯基)戊-1-醇;
1-(6-溴-2-(1H-四唑-5-基)吡啶-3-基)戊-1-醇;
1-(6-溴-2-(1-甲基-1H-四唑-5-基)吡啶-3-基)戊-1-醇;
1-(4-氯-2-(1-甲基-1H-四唑-5-基)苯基)戊-1-醇;
1-(6-氯-2-(1H-四唑-5-基)吡啶-3-基)戊-1-醇;
1-(6-氯-2-(1-甲基-1H-四唑-5-基)吡啶-3-基)戊-1-醇;
1-(4-氟-2-(1-甲基-1H-四唑-5-基)苯基)戊-1-醇;
1-(6-氟-2-(1H-四唑-5-基)吡啶-3-基)戊-1-醇;
1-(6-氟-2-(1-甲基-1H-四唑-5-基)吡啶-3-基)戊-1-醇;
1-(2-(1-甲基-1H-四唑-5-基)苯基)戊-1-醇;
1-(2-(1H-四唑-5-基)吡啶-3-基)戊-1-醇;
1-(2-(1-甲基-1H-四唑-5-基)吡啶-3-基)戊-1-醇;
1-(4-氨基-2-(1H-四唑-5-基)苯基)戊-1-醇;
1-(4-氨基-2-(1-甲基-1H-四唑-5-基)苯基)戊-1-醇;
1-(4-硝基-2-(1H-四唑-5-基)苯基)戊-1-醇;
1-(4-硝基-2-(1-甲基-1H-四唑-5-基)苯基)戊-1-醇;
1-(2-(1H-四唑-5-基)-4-(三氟甲基)苯基)戊-1-醇;
1-(2-(1-甲基-1H-四唑-5-基)-4-(三氟甲基)苯基)戊-1-醇;
1-(4-溴-2-(1H-四唑-5-基)苯基)戊-1-醇;
1-(4-溴-2-(1H-四唑-5-基)苯基)丁-1-醇;
1-(4-溴-2-(1-甲基-1H-四唑-5-基)苯基)丁-1-醇;
1-(4-溴-2-(1H-四唑-5-基)苯基)己-1-醇;
1-(4-溴-2-(1-甲基-1H-四唑-5-基)苯基)己-1-醇;
1-(4-氯-2-(1H-四唑-5-基)苯基)戊-1-醇;
1-(4-氯-2-(1H-四唑-5-基)苯基)丁-1-醇;
1-(4-氯-2-(1-甲基-1H-四唑-5-基)苯基)丁-1-醇;
1-(4-氯-2-(1H-四唑-5-基)苯基)己-1-醇;
1-(4-氯-2-(1-甲基-1H-四唑-5-基)苯基)己-1-醇;
1-(4-氟-2-(1H-四唑-5-基)苯基)戊-1-醇;
1-(4-氟-2-(1H-四唑-5-基)苯基)丁-1-醇;
1-(4-氟-2-(1-甲基-1H-四唑-5-基)苯基)丁-1-醇;
1-(4-氟-2-(1H-四唑-5-基)苯基)己-1-醇;
1-(4-氟-2-(1-甲基-1H-四唑-5-基)苯基)己-1-醇;
1-(2-(1H-四唑-5-基)苯基)戊-1-醇;
1-(2-(1H-四唑-5-基)苯基)丁-1-醇;
1-(2-(1-甲基-1H-四唑-5-基)苯基)丁-1-醇;
1-(2-(1H-四唑-5-基)苯基)己-1-醇;
1-(2-(1-甲基-1H-四唑-5-基)苯基)己-1-醇;
1-(5-溴-2-(1H-四唑-5-基)苯基)戊-1-醇;
1-(5-溴-2-(1H-四唑-5-基)苯基)己-1-醇
或上述化合物的其他光学异构体;或上述化合物药学上可接受的盐或溶剂合物;或其光学异构体药学上可接受的盐或溶剂合物。
具体地,根据通式I,本发明优选的化合物为:
及其上述化合物的光学异构体;或其药学上可接受的盐或溶剂合物。
或上述化合物的其他光学异构体;或上述化合物的药学上可接受的溶剂合物。
作为优选,所述药学上可接受的盐是与下列碱中的一种或多种所形成的盐:氢氧化钠,氢氧化钾,氢氧化锂,甲醇钠,甲醇钾,乙醇钠,乙醇钾,三乙胺,叔丁胺。
作为优选,所述的四氮唑类衍生物包括:
1-(6-溴-2-(1H-四唑-5-基)吡啶-3-基)戊-1-醇钠盐
1-(6-溴-2-(1H-四唑-5-基)吡啶-3-基)戊-1-醇钾盐
1-(6-溴-2-(1H-四唑-5-基)吡啶-3-基)戊-1-醇锂盐
1-(6-溴-2-(1H-四唑-5-基)吡啶-3-基)戊-1-醇三乙胺盐
1-(6-溴-2-(1H-四唑-5-基)吡啶-3-基)戊-1-醇叔丁胺盐
1-(2-(1H-四唑-5-基)-4-(三氟甲基)苯基)戊-1-醇钠盐
1-(2-(1H-四唑-5-基)-4-(三氟甲基)苯基)戊-1-醇钾盐
1-(2-(1H-四唑-5-基)-4-(三氟甲基)苯基)戊-1-醇锂盐
1-(2-(1H-四唑-5-基)-4-(三氟甲基)苯基)戊-1-醇三乙胺盐
1-(2-(1H-四唑-5-基)-4-(三氟甲基)苯基)戊-1-醇叔丁胺盐
1-(4-氨基-2-(1H-四唑-5-基)苯基)戊-1-醇钠盐
1-(4-氨基-2-(1H-四唑-5-基)苯基)戊-1-醇钾盐
1-(4-氨基-2-(1H-四唑-5-基)苯基)戊-1-醇锂盐
1-(4-氨基-2-(1H-四唑-5-基)苯基)戊-1-醇三乙胺盐
1-(4-氨基-2-(1H-四唑-5-基)苯基)戊-1-醇叔丁胺盐
1-(4-溴-2-(1H-四唑-5-基)苯基)戊-1-醇钠盐
1-(4-溴-2-(1H-四唑-5-基)苯基)戊-1-醇钾盐
1-(4-溴-2-(1H-四唑-5-基)苯基)戊-1-醇锂盐
1-(4-溴-2-(1H-四唑-5-基)苯基)戊-1-醇三乙胺盐
1-(4-溴-2-(1H-四唑-5-基)苯基)戊-1-醇叔丁胺盐
或上述化合物的其他光学异构体;或上述化合物的药学上可接受的溶剂合物。
作为优选,所述的四氮唑类衍生物包括:
(R)-1-(4-溴-2-(1H-四唑-5-基)苯基)戊-1-醇
(S)-1-(4-溴-2-(1H-四唑-5-基)苯基)戊-1-醇
(R)-1-(4-氯-2-(1H-四唑-5-基)苯基)戊-1-醇
(S)-1-(4-氯-2-(1H-四唑-5-基)苯基)戊-1-醇
(R)-1-(4-氟-2-(1H-四唑-5-基)苯基)戊-1-醇
(S)-1-(4-氟-2-(1H-四唑-5-基)苯基)戊-1-醇
(R)-1-(4-溴-2-(1H-四唑-5-基)苯基)己-1-醇
(S)-1-(4-溴-2-(1H-四唑-5-基)苯基)己-1-醇
(R)-1-(4-氯-2-(1H-四唑-5-基)苯基)己-1-醇
(S)-1-(4-氯-2-(1H-四唑-5-基)苯基)己-1-醇
(R)-1-(4-氟-2-(1H-四唑-5-基)苯基)己-1-醇
(S)-1-(4-氟-2-(1H-四唑-5-基)苯基)己-1-醇
(R)-1-(5-溴-2-(1H-四唑-5-基)苯基)戊-1-醇
(S)-1-(5-溴-2-(1H-四唑-5-基)苯基)戊-1-醇
(R)-1-(5-溴-2-(1H-四唑-5-基)苯基)己-1-醇
(S)-1-(5-溴-2-(1H-四唑-5-基)苯基)己-1-醇
或上述化合物的其他光学异构体;或上述化合物的药学上可接受的溶剂合物。
一种所述的四氮唑类衍生物的制备方法,化合物(1)与酰基保护试剂反应,得到化合物(2),化合物(2)再与叠氮钠反应,然后加入盐酸同时脱除保护基与消除剩余叠氮化钠,得到化合物(3),化合物(3)与格氏试剂反应即可得到式(I)所示的化合物;可选择,所述式(I)所示的化合物再与烷基化试剂反应得到四氮唑烷基取代产如式(I’)所示化合物:
作为优选,所述酰基保护试剂为乙二醇。
所述化合物(1)可以由式(1-1)所述的化合物为原料,经过溴代、水解得到:
由化合物(1-1)制备化合物(1-2)时,溴代试剂采用NBS,可选择加入引发剂AIBN,反应溶剂为四氯化碳,反应温度为回流温度,反应时间为10~24小时。
其中溴代试剂与化合物(1-1)的摩尔比为1.5~3:1。反应完成后,直接加入水和乙醇(1:1)以及与化合物相同当量的硝酸银,进行第二步的水解反应,反应温度为60~80℃。反应时间为4小时。
作为优选,所述化合物(1)与酰基保护试剂反应的温度为70~130℃;反应试剂可以选择甲苯,催化剂选择对甲苯磺酸。其中乙二醇与化合物(1)的摩尔比为1~10:1,进一步优选为2~8:1,更进一步优选为4~7:1。对甲苯磺酸与化合物(1)的摩尔比为0.03~0.2:1,进一步优选为0.05~0.1:1。
作为优选,所述化合物(2)与叠氮钠反应的温度为110~170℃。其中加入氯化铵,反应溶剂为DMF,反应完成后利用稀盐酸进行猝灭。所述叠氮钠与化合物(2)的摩尔比为2~10:1,进一步优选为4~7:1。氯化铵与化合物(2)的摩尔比为2~10:1,进一步优选为4~7:1。
所述格式试剂可以采用市售产品,也可以现场制备。可以由溴代C
3-C
5烷烃与镁反应得到,制备过程中,可加入碘颗粒。溴代C
3-C
5烷烃摩尔量计算,其与化合物(2)的摩尔比为2~10:1,进一步优选为4~7:1。
作为优选,所述化合物(3)与烷基化试剂(碘代汀)的反应温度为30~50℃,反应溶剂选择DMF,催化剂选择钠氢。其中碘代烃与化合物(3)的摩尔比为1~2:1,更进一步优选为1~1.5:1。钠氢与化合物(3)的摩尔比为2~3:1,更进一步优选为2.5~3:1。
一种药物组合物,所述药物组合物包含至少一种活性组分以及一种或多种药学上可接受的载体或赋形剂,所述的活性组分为上述任一项技术方案所述的四氮唑类衍生物。
一种上述任一项技术方案所述四氮唑类衍生物在制备预防和对抗心脑血管性疾病、改善心脑血管循环障碍或抗血栓的药物中的应用。
本文所用术语“药学可接受衍生物”是指所选化合物的盐和溶剂合物。
本文所用术语“烷基”是指碳原子直链或含支链烷烃基团,本文所用“烷基”的实例包括但不限于甲基、乙基、正丙基、异丙基等,“烷基”还包括取代烷基。烷基可任选被卤素取代一次或多次。
本文所用术语“卤素”表示氟、氯、溴或碘,优选为氟、氯或溴。
本文所用术语“溶剂合物”是指由溶质(例如:本发明的通式(I))和溶剂形成的可变化学计量的复合物。为了本发明的目的,所述溶剂不能干扰溶质的生物学活性。合适的溶剂的实例包括但不限于水、甲醇、乙醇和乙酸。优选使用的溶剂为药学可接受溶剂。合适的药学可接受溶剂包括但不限于水、乙醇和乙酸。更优选地,所用溶剂为水。
本发明采用本领域技术人员所熟知的方法可以制备本发明所述的四氮唑类化合物的盐。所述的盐可以是有机碱盐、无机碱盐等,所述的有机碱盐包括甲醇钠,甲醇钾,乙醇钠,乙醇钾,三乙胺,叔丁胺等;所述的无机碱盐包括氢氧化钠,氢氧化钾, 氢氧化锂等。
本发明的第二个目的是提供一种药物组合物,所述药物组合物包含至少一种活性组分以及一种或多种药学上可接受的载体或赋形剂,所述的活性组分可以是本发明通式(I)所示结构的四氮唑类化合物及其优选化合物、所述化合物的光学异构体、所述化合物或其光学异构体在药学上可接受的盐、所述化合物或其光学异构体的溶剂合物中的任意一种或任意多种。
所述载体包括药学领域的常规稀释剂、赋形剂、填充剂、粘合剂、湿润剂、崩解剂、吸收促进剂、表面活性剂、吸附载体、润滑剂等中的一种或多种,必要时还可以加入香味剂、甜味剂等。本发明药物可以制成片剂、粉剂、粒剂、胶囊、口服液及注射用药等多种形式,上述各剂型的药物均可以按照药学领域的常规方法制备。
本发明还提供(I)所述的化合物、及其光学异构体或其药学上可接受的盐或溶剂合物在制备预防和对抗心脑血管性疾病、改善心脑血管循环障碍、或抗血栓的药物中的用途。
本发明还提供本发明所述的化合物或其可药用盐在制备预防和对抗心脑血管性疾病、改善心脑血管循环障碍、或抗血栓的药物中的用途,特别是在制备治疗急性缺血性脑卒中中的应用。换言之,本发明提供四氮唑类化合物或其可药用盐单独或和其他药物联合使用在治疗急性缺血性脑卒中中的应用。能和本发明所提供的化合物或其可药用盐联合使用的抗脑卒中药物包括但并非限定至少一种以下种类:自由基清除剂(如依达拉奉);神经保护剂(如施普善);抗血小板药物(如氯吡格雷、阿司匹林);抗血栓药物(如利伐沙班)。
本发明发明人通过多次实验证实,本发明化合物对ADP诱导的血小板聚集具有抑制活性以及良好的大鼠口服药代动力学性质。因此,本发明化合物可作为神经保护剂应用于制备治疗和预防急性缺血性脑卒中的药物中。
图1阳性药丁苯酞(NBP)和BZP的结构;
图2化合物对OGD/R造模的胎鼠原代皮层神经元细胞保护作用;
图3化合物对OGD/R造模的神经母细胞瘤细胞(N2A)诱导的神经元样细胞的保护作用;其中*p<0.05,***p<0.001vs.indicated group n=12.Error bars,SEM;
图4化合物在线栓法短暂性大脑中动脉阻塞构建局灶性脑缺血动物模型中的药效作用;其中#p<0.05,##p<0.01,###p<0.001versus vehicle group;*p<0.05versus NBP group.Error bars,SEM。
下面通过实施例来说明本发明的可实施性,本领域的技术人员应当理解,根据现有技术的教导,对相应的技术特征进行修改或替换,仍然属于本发明要求保护的范围。
实施例1.中间体1-3的合成
在三颈瓶中加入原料1-1(13.2g,0.1mol),NBS(N-溴代丁二酰亚胺)(44.5g,0.25mol),AIBN(偶氮二异丁腈)(720mg,3mmol),四氯化碳(20ml),加热回流16h,冷却至室温,减压浓缩除去四氯化碳,得到含中间体1-2的混合物。混合物中加入水和乙醇(100ml:100ml),70摄氏度反应4h,乙酸乙酯萃取得有机相,无水硫酸钠干燥,减压浓缩蒸干乙酸乙酯,所得粗产品用硅胶柱层析(乙酸乙酯:石油醚=1:50-1:10)纯化得白色至淡黄色结晶中间体1-3约8.4g,收率40%,纯度大于99%。HRMS:m/z(ESI)calcd for C
8H
6N
2O[M+H]
+147.05found:147.67。
实施例2:中间体1-5的合成
步骤一:在单颈瓶中加入中间体1-3(2.8g,20mmol),乙二醇(6.2g,0.1mol),甲苯(20ml),对甲苯磺酸(275mg,1.6mmol)加热回流,使用分水器分去水至分水器中水量不再增加,冷却至室温。加入饱和碳酸氢钠溶液至水层为中性或碱性,分去水层,有机层减压浓缩,得到4.5g浅黄色油状半固体中间体1-4。收率89%。纯度大于99%。
步骤二:单颈瓶加入中中间体1-4(0.7g,3.93mmol),叠氮化钠(1.28g,19.65mmol),氯化铵(1.05g,19.65mmol),和DMF(10ml),加热回流12h,冷却至室温,加入1N盐酸淬灭,室温搅拌1h,TLC确认脱去保护基后,乙酸乙酯萃取得到有机相,减压浓缩除去乙酸乙酯,所得粗产品用硅胶柱层析(二氯甲烷:甲醇=10:1)纯化得924mg中间体1-5。收率93%,HRMS:m/z(ESI)calcd for C
8H
7N
5O[M-H]
-189.07found:189.56。
实施例3:中间体2-3的合成
参考实施例1的步骤,5-(三氟甲基)-2-甲基苯腈2-1(18.5g,0.1mol)为原料,得15.2g固体2-3,收率76%,纯度大于99%,HRMS:m/z(ESI)calcd for C
9H
4F
3NO[M+H]
+200.02found:200.25。
实施例4:中间体2-5的合成
参考实施例2的步骤一、二,用中间体2-3代替中间体1-3,以中间体2-4代替中间体1-4,得2.3g固体2-5,收率56%(两步),纯度大于99%,HRMS:m/z(ESI)calcd for C
9H
5F
3N
4O[M-H]
-241.04found:240.89。
实施例5:中间体3-1的合成
参考实施例1的步骤,5-硝基-2-甲基苯腈3-1(16.2g,0.1mol)为原料,得8.9g固体3-3,收率50%,纯度大于99%,HRMS:m/z(ESI)calcd for C
8H
4N
2O
3[M+H]
+177.02found:177.23。
实施例6:中间体3-5的合成
参考实施例2的步骤一、二,用中间体3-3代替中间体1-3,以中间体3-4代替中间体1-4,得3.5g固体3-5,收率72%(两步),纯度大于99%,HRMS:m/z(ESI)calcd for C
8H
5N
5O
3[M-H]
-218.04found:217.92。
实施例7:中间体4-3的合成
参考实施例1的步骤,以6-溴-3-甲基吡啶啉4-1(19.5g,0.1mol)为原料,得6.2g固体4-3,收率29%,纯度大于99%,HRMS:m/z(ESI)calcd for C
7H
3BrN
2O[M+H]
+210.94found:211.05。
实施例8:中间体4-5的合成
参考实施例2的步骤一、二,用中间体4-3代替中间体1-3,以中间体4-4代替中间体1-4,得2.2g固体4-5,收率35%(两步),纯度大于99%,HRMS:m/z(ESI)calcd for C
7H
4BrN
5O[M-H]
-251.96found:252.05。
实施例9:中间体5-3的合成
参考实施例1的步骤,以5-溴-2-甲基苯腈5-1(19.4g,0.1mol)为原料,得6.2g固体5-3,收率29%,纯度大于99%,HRMS:m/z(ESI)calcd for C
8H
4BrNO[M+H]
+209.95found:210.10。
实施例10:中间体5-5的合成
参考实施例2的步骤一、二,用中间体5-3代替中间体1-3,以中间体5-4代替中间体1-4,得2.6g固体5-5,收率37%(两步),纯度大于99%,HRMS:m/z(ESI)calcd for C
8H
5BrN
4O[M-H]
-250.96found:251.32。
实施例11:中间体6-3的合成
参考实施例1的步骤,5-氯-2甲基苯腈6-1(15.1g,0.1mol)为原料,得7.3g固体6-3,收率44%,纯度大于99%,HRMS:m/z(ESI)calcd for C
8H
4ClNO[M+H]
+166.00found:166.23。
实施例12:中间体6-5的合成
参考实施例2的步骤一、二,用中间体6-3代替中间体1-3,以中间体6-4代替中间体1-4,得3.2g白色固体6-5,收率65%(两步),纯度大于99%,HRMS:m/z(ESI)calcd for C
8H
5ClN
4O[M-H]
-207.02found:206.95。
实施例13:中间体7-3的合成
参考实施例1的步骤,5-氟-2甲基苯腈7-1(13.5g,0.1mol)为原料,得4.5g固体7-3,收率30%,纯度大于99%,HRMS:m/z(ESI)calcd for C
8H
4FNO[M+H]
+150.03found:149.68。
实施例14:中间体7-5的合成
参考实施例2的步骤一、二,用中间体7-3代替中间体1-3,以中间体7-4代替中间体1-4,得1.9g固体7-5,收率39%(两步),纯度大于99%,HRMS:m/z(ESI)calcd for C
8H
5FN
4O[M-H]
-191.04found:191.25。
实施例15:中间体8-5的合成
参考实施例2的步骤一、二,以2-甲酰基苯甲腈8-3(13g,0.1mol)为原料,以中间体8-4代替中间体1-4,得6g固体8-5,收率34%(两步),纯度大于99%,HRMS:m/z(ESI)calcd for C
7H
5N
5O[M-H]
-173.05found:173.55。
实施例16:中间体9-3的合成
参考实施例1的步骤,以(15.2g,0.1mol)6-氯-3-甲基吡啶啉9-1为原料,得6.9g固体9-3,收率41%,纯度大于99%,HRMS:m/z(ESI)calcd for C
7H3ClN
2O[M+H]
+166.99found:167.20。
实施例17:中间体9-5的合成
参考实施例2的步骤一、二,用中间体9-3代替中间体1-3,以中间体9-4代替中间体1-4,得3.5g固体9-5,收率69%(两步),纯度大于99%,HRMS:m/z(ESI)calcd for C
7H
4BrN
5O[M-H]
-251.96found:252.05。
实施例18:中间体10-3的合成
参考实施例1的步骤,5-氟-2甲基苯腈10-1(13.6g,0.1mol)为原料,得7.5g固体10-3,收率50%,纯度大于99%,HRMS:m/z(ESI)calcd for C
7H
3BrN
2O[M+H]
+151.02found:151.20。
实施例19:中间体10-5的合成
参考实施例2的步骤一、二,用中间体10-3代替中间体1-3,以中间体10-4代替中间体1-4,得2.7g固体10-5,收率64%(两步),纯度大于99%,HRMS:m/z(ESI)calcd for C
7H
4BrN
5O[M-H]
-192.04found:191.89。
实施例20:中间体11-5的合成
参考实施例2的步骤一、二,以(13.2g,0.1mol)3-甲酰基吡啶啉11-3为原料,以中间体11-4代替中间体1-4,得4.5g固体11-5,收率25%(两步),纯度大于99%,HRMS:m/z(ESI)calcd for C
7H
5N
5O[M-H]
-174.05found:173.99。
实施例21:目标化合物Ⅴ-1的合成
在三颈瓶中加入溴丁烷(688.84mg,5.03mmol),碘粒(100mg,0.39mmol),金属镁条(100.56mg,4.19mmol),10ml无水四氢呋喃,氮气保护,加热回流12h,在三颈瓶中用15mL无水四氢呋喃溶解189mg中间体1-5,氮气保护,将所制备格式试剂在冰浴条件下注入,室温反应10h,所得粗产品用硅胶柱层析(二氯甲烷:甲醇=10:1)纯化得210mg目标化合物Ⅴ-1,纯度大于99%。
1HNMR(CD
3OD,500MHz)δ:0.70(t,3H,CH
3),0.96~1.25(m,6H,CH
2),4.23(t,1H,C(OH)H),7.56(d,1H,ArH),7.75(dd,1H,ArH),7.97(d,1H,ArH)。HRMS:m/z(ESI)calcd for C
12H
17N
5O[M-H]
-246.14found:246.77。
实施例22:目标化合物Ⅴ-2的合成
在单颈瓶中加入(100mg,0.404mmol)V-1,钠氢(30mg,1.209mmol),10ml无水DMF,氮气保护,45℃反应0.5h,用注射器注入(60mg,0.404mmol)碘甲烷,38℃反应4h,所得粗产品用硅胶柱层析(二氯甲烷:甲醇=10:1)纯化得30mg目标化合物Ⅴ-2。纯度大于99%。
1HNMR(CDCl
3,500MHz)δ:0.71(t,3H,CH
3),0.85~1.35(m,6H,CH
2),4.15(t,1H,C(OH)H),4.65(s,3H,N-CH3)7.77(d,1H,ArH),7.85(dd,1H,ArH),8.01(d,1H,ArH)。HRMS:m/z(ESI)calcd for C
13H
19N
5O[M+H]
+262.16found:262.35。
实施例23:目标化合物Ⅴ-3的合成
参考实施例21的步骤,用中间体2-5代替中间体1-5,得120mg目标化合物Ⅴ-3,收率62%,纯度大于99%。
1HNMR(CD
3OD,500MHz)δ:0.85(t,3H,CH
3),0.9~1.25(m,6H,CH
2),4.13(t,1H,C(OH)H),8.25(d,1H,ArH),8.65(dd,1H,ArH),8.77(d,1H,ArH)。HRMS:m/z(ESI)calcd for C
13H
15F
3N
4O[M-H]
-299.12found:299.25。
实施例24:目标化合物V-4的合成
参考实施例22的步骤,用V-3代替V-1,得30mg目标化合物V-4,收率65%,纯度大于99%。
1HNMR(CDCl
3,500MHz)δ:0.86(t,3H,CH
3),0.95~1.29(m,6H,CH
2),4.37(t,1H,C(OH)H),4.72(s,3H,N-CH3),8.13(d,1H,ArH),8.77(dd,1H,ArH),8.85(d,1H,ArH)。HRMS:m/z(ESI)calcd for C
14H
17F
3N
4O[M+H]
+315.14found:315.26。
实施例25:目标化合物V-5的合成
参考实施例21的步骤,用中间体3-5代替中间体1-5,得80mg目标化合物V-5,收率35%,纯度大于99%。
1HNMR(CD
3OD,500MHz)δ:0.67(t,3H,CH
3),0.72~1.26(m,6H,CH
2),4.51(t,1H,C(OH)H),8.13(d,1H,ArH),8.35(dd,1H,ArH),8.75(d,1H,ArH)。HRMS:m/z(ESI)calcd for C
12H
15N
5O
3[M-H]
-276.12found:276.25。
实施例26:目标化合物V-6的合成
参考实施例22的步骤,用V-5代替V-1,得40mg目标化合物V-6,收率78%,纯度大于99%。
1HNMR(CDCl
3,500MHz)δ:0.69(t,3H,CH
3),0.75~1.27(m,6H,CH
2),4.25(s,3H,N-CH3),4.37(t,1H,C(OH)H),7.95(d,1H,ArH),8.23(dd,1H,ArH),8.64(d,1H,ArH)。HRMS:m/z(ESI)calcd for C
12H
17N
5O[M+H]
+292.13found:292.25。
实施例27:目标化合物V-7的合成
参考实施例21的步骤,用中间体4-5代替中间体1-5,得168mg目标化合物V-7,收率69%,纯度大于99%。
1HNMR(CD
3OD,500MHz)δ:0.69(t,3H,CH
3),1.24~1.45(m,6H,CH
2),4.57(t,1H,C(OH)H),7.24(d,1H,ArH),7.69(d,1H,ArH)。HRMS:m/z(ESI)calcd for C
11H
14BrN
5O[M-H]
-310.04found:309.88。
实施例28:目标化合物V-8的合成
参考实施22的步骤,用V-7代替V-1,得30mg目标化合物V-8,纯度大于99%。
1HNMR(CD
3OD,500MHz)δ:0.71(t,3H,CH
3),0.83~1.25(m,6H,CH
2),3.95(s,3H,N-CH3),4.67(t,1H,C(OH)H),7.69(d,1H,ArH),8.13(d,1H,ArH)。HRMS:m/z(ESI)calcd for C
12H
16BrN
5O[M+H]
+326.05found:325.69。
实施例29:目标化合物V-9的合成
步骤一:
参考实施例21和实施例22的步骤,用中间体5-5代替V-1,得到中间体V-9a,
1HNMR(500MHz,CDCl
3)δ:0.79(t,3H,CH
3),1.24(m,6H,CH
2),7.69(d,1H,ArH),7.77(dd,1H,ArH),7.87(d,1H,ArH)。收率90%,纯度大于99%,ESI(M-H)
-=310。
步骤二:
用V-9a代替V-1得30mg目标化合物V-9,纯度大于99%。
1HNMR(CDCl
3,500MHz) δ:0.71(t,3H,CH
3),0.83~1.25(m,6H,CH
2),4.35(s,3H,N-CH3),4.44(t,1H,C(OH)H),7.24(d,1H,ArH),7.75(dd,1H,ArH),7.89(d,1H,ArH)。HRMS:m/z(ESI)calcd for C
13H
17BrN
4O[M+H]
+325.06found:325.45。
实施例30:目标化合物V-10的合成
步骤一:
参考实施例21和实施例22的步骤,用中间体6-5代替V-1,得到中间体V-10a,收率85%,纯度大于99%,1H NMR(500MHz,Methanol-d
4)δ7.76(dd,J=8.8,5.7Hz,1H),7.42(dd,J=9.3,2.7Hz,1H),7.33(td,J=8.5,2.8Hz,1H),5.12(t,J=6.5Hz,1H),1.62(q,J=6.8Hz,2H),1.48–1.18(m,4H),0.85(t,J=7.1Hz,3H).ESI(M-H)
-=265。
步骤二:
用V-10a代替V-1得45mg目标化合物V-10,纯度大于99%。
1HNMR(CDCl
3,500MHz)δ:0.79(t,3H,CH
3),0.85~1.35(m,6H,CH
2),4.39(t,1H,C(OH)H),4.56(s,3H,N-CH3),7.35(d,1H,ArH),7.67(dd,1H,ArH),7.98(d,1H,ArH)。HRMS:m/z(ESI)calcd for C
13H
17ClN
4O[M+H]
+281.11found:281.25。
实施例31:目标化合物V-11的合成
步骤一:
参考实施例21和实施例22的步骤,用7-5代替V-1,得到中间体V-11a,收率86%,纯度大于99%,
1H NMR(500MHz,Methanol-d4)δ7.74(d,J=8.5Hz,1H),7.69(d,J=2.3Hz,1H),7.59(dd,J=8.5,2.2Hz,1H),5.14(dd,J=7.5,5.3Hz,1H),1.67–1.50(m,2H),1.48–1.36(m,1H),1.35–1.12(m,5H),0.86(t,J=7.0Hz,3H).ESI(M-H)
-=249。
步骤二:
用V-11a代替V-1得35mg目标化合物V-11,纯度大于99%。
1HNMR(CDCl
3,500MHz)δ:0.67(t,3H,CH
3),0.75~1.24(m,6H,CH
2),4.36(s,3H,N-CH3),4.41(t,1H,C(OH)H),7.68(d,1H,ArH),7.98(dd,1H,ArH),8.12(d,1H,ArH)HRMS:m/z(ESI)calcd for C
13H
17FN
4O[M+H]
+265.14found:265.39。
实施例32:目标化合物V-12的合成
步骤一:
参考实施例21和实施例22的步骤,用中间体8-5代替V-1,收率90%,纯度大于99%,
1HNMR(500MHz,CDCl
3)δ:0.90(t,3H,CH3,J=7.5Hz),1.35-2.05(m,6H,CH2),5.44(q,1H,CH,J=5Hz),7.26(s,1H,ArH),7.32(d,1H,ArH,J=1Hz),7.78(dd,1H,ArH,J=7.5,1Hz),8.02(d,1H,ArH,J=7.5Hz)。ESI(M-H)
-=231。
步骤二:
用V-12a代替V-1得40mg目标化合物V-12,纯度大于99%。
1HNMR(CDCl
3,500MHz)δ:0.68(t,3H,CH
3),0.72~1.05(m,6H,CH
2),3.98(s,3H,N-CH3),4.37(t,1H,C(OH)H),7.27(d,1H,ArH),7.48(m,1H,ArH),7.58(m,1H,ArH),7.82(d,1H,ArH)。HRMS:m/z(ESI)calcd for C
13H
18N
4O[M+H]
+247.15found:247.29。
实施例33:目标化合物V-13的合成
参考实施例21的步骤,用中间体9-5代替中间体1-5,得69mg目标化合物V-13,收率38%,纯度大于99%。
1HNMR(CD
3OD,500MHz)δ:0.72(t,3H,CH
3),0.85~1.12(m,6H,CH
2),4.27(t,1H,C(OH)H),7.69(d,1H,ArH),7.98(d,1H,ArH)。HRMS:m/z(ESI)calcd for C
11H
14ClN
5O[M-H]
-266.09found:265.79。
实施例34:目标化合物V-14的合成
参考实施例22的步骤,用V-13代替V-1,得36mg目标化合物V-14,纯度大于99%。
1HNMR(CD
3OD,500MHz)δ:0.69(t,3H,CH
3),0.79~1.24(m,6H,CH
2),4.29(t,1H,C(OH)H),4.35(s,3H,N-CH3),7.86(d,1H,ArH),8.02(d,1H,ArH)。HRMS:m/z(ESI)calcd for C
12H
16ClN
5O[M+H]
+282.10found:282.64。
实施例35:目标化合物V-15的合成
参考实施例21的步骤,用中间体10-5代替中间体1-5,得135mg目标化合物V-15,收率64%,纯度大于99%。
1HNMR(CD
3OD,500MHz)δ:0.76(t,3H,CH
3),0.87~1.35(m,6H,CH
2),4.39(t,1H,C(OH)H),7.67(d,1H,ArH),8.24(d,1H,ArH)。HRMS:m/z(ESI)calcd for C
11H
14FN
5O[M-H]
-250.12found:250.15。
实施例36:目标化合物V-16的合成
参考实施例22的步骤,用V-15代替V-1,得65mg目标化合物V-16,收率64%,纯度大于99%。
1HNMR(CD
3OD,500MHz)δ:0.75(t,3H,CH
3),0.85~1.31(m,6H,CH
2),4.46(s,3H,N-CH3),4.55(t,1H,C(OH)H),7.99(d,1H,ArH),8.23(d,1H,ArH)。HRMS:m/z(ESI)calcd for C
12H
16FN
5O[M+H]
+266.13found:266.36。
实施例37:目标化合物V-17的合成
参考实施例21的步骤,用中间体11-5代替中间体1-5,得116mg目标化合物V-17,收率59%,纯度大于99%。
1HNMR(CD
3OD,500MHz)δ:0.72(t,3H,CH
3),0.85~0.98(m,6H,CH
2),4.43(t,1H,C(OH)H),7.34(d,1H,ArH),7.86(m,1H,ArH),8.42(d,1H,ArH)。HRMS:m/z(ESI)calcd for C
11H
15N
5O[M-H]
-232.13found:232.15。
实施例38:目标化合物V-18的合成
参考实施例13的步骤,用V-17代替V-1,得62mg目标化合物V-18,收率93%,纯度大于99%。
1HNMR(CD
3OD,500MHz)δ:0.67(t,3H,CH
3),0.82~1.21(m, 6H,CH
2),4.35(s,3H,N-CH3),4.45(t,1H,C(OH)H),7.45(d,1H,ArH),7.86(m,1H,ArH),8.55(d,1H,ArH)。HRMS:m/z(ESI)calcd for C
12H
17N
5O[M+H]
+248.14found:247.99。
实施例39.中间体4-5-3的合成
参考实施例1的合成方法,将原料1-1替换成4-5-1得到中间体4-5-3,ESI(M+H)
+=210。
实施例40.中间体4-5-5的合成
参考实施例2的合成方法,将原料1-3替换成4-5-3得到中间体4-5-5,ESI(M-H)
-=251。
实施例41.目标化合物V-19的合成
参考实施例21的步骤,用中间体8-5代替中间体1-5,用溴丙烷代替溴丁烷,得160mg目标化合物V-19,收率83%,纯度大于99%,
1HNMR(500MHz,CDCl
3)δ:0.82(t,3H,CH3,J=7.5Hz),1.25-1.63(m,4H,CH2),5.01(q,1H,CH,J=5Hz),7.39(td,1H,ArH,J=7.5,1Hz),7.52(td,1H,ArH,J=7.5,1Hz),7.60(dd,1H,ArH,J=7.5,1Hz),7.67(td,1H,ArH,J=7.5Hz)。ESI(M-H)
-=217。
实施例42.目标化合物V-20的合成
参考实施例21的步骤,用中间体8-5代替中间体1-5,用溴戊烷代替溴丁烷,得203mg目标化合物V-20,收率93%,
1HNMR(500MHz,CDCl
3)δ:0.85-1.62(m,8H,CH2),1.37(m,3H,CH3),5.07(t,1H,CH,J=6.5Hz),7.43(td,1H,ArH,J=8,1.5Hz),7.58(t,2H,ArH,J=7.5Hz),7.43(d,1H,ArH,J=7.5Hz)。ESI(M-H)
-=245。
实施例43.目标化合物V-21的合成
参考实施例21的步骤,用中间体5-5代替中间体1-5,用溴戊烷代替溴丁烷,得到目标化合物V-21,收率91%,
1H NMR(500MHz,Methanol-d
4)δ7.74(d,J=8.5Hz,1H),7.69(d,J=2.3Hz,1H),7.62–7.56(m,1H),5.14(dd,J=7.7,5.2Hz,1H),1.69–1.52(m,2H),1.38(tdd,J=10.9,6.0,2.6Hz,1H),1.33–1.19(m,3H),0.85(t,J=7.1Hz,3H).ESI(M-H)
-=323。
实施例44.目标化合物V-22的合成
参考实施例21的步骤,用中间体6-5代替中间体1-5,用溴戊烷代替溴丁烷,得到目标化合物V-22,收率95%,
1H NMR(500MHz,Methanol-d
4)δ7.83(d,J=2.1Hz,1H),7.74(dd,J=8.5,2.1Hz,1H),7.68(d,J=8.4Hz,1H),5.13(dd,J=7.7,5.2Hz,1H),1.69–1.51(m,2H),1.41(dtd,J=11.9,7.1,5.7,2.8Hz,1H),1.35–1.08(m,4H),0.86(t,J=7.0Hz,3H).ESI(M-H)
-=279。
实施例45:目标化合物V-23的合成
参考实施例21的步骤,用中间体7-5代替中间体1-5,用溴戊烷代替溴丁烷,得到目标化合物V-23,收率89%,ESI(M-H)
-=263。
实施例46:目标化合物Ⅴ-24的合成
参考实施例21的步骤,用中间体4-5-5代替中间体1-5,得到目标化合物Ⅴ-24,
1H NMR(500MHz,Methanol-d4)δ7.92(d,J=2.0Hz,1H),7.60(dd,J=8.3,2.1Hz,1H),7.55(d,J=8.3Hz,1H),5.16(dd,J=8.3,4.4Hz,1H),1.68–1.49(m,2H),1.46–1.14(m,3H),0.85(t,J=7.2Hz,3H)。ESI(M-H)
-=310。
实施例47:目标化合物Ⅴ-25的合成
参考实施例21的步骤,用4-5-5代替1-5,得到目标化合物Ⅴ-25,ESI(M-H)
-=323。
实施例48:目标化合物Ⅴ-26的合成
参考实施例21的步骤,用5-5代替1-5,用溴丙烷代替溴丁烷,得到目标化合物Ⅴ-26,ESI(M-H)
-=295。
实施例49:目标化合物V-27的合成
参考实施例21的步骤,用6-5代替1-5,用溴丙烷代替溴丁烷,得到目标化合物V-27,ESI(M-H)
-=251。
实施例50:目标化合物V-28的合成
参考实施例21的步骤,用7-5代替1-5,用溴丙烷代替溴丁烷,得到目标化合物V-28,ESI(M-H)
-=235。
实施例51:目标化合物Ⅴ-29的合成
参考实施例22的步骤,用V-26代替V-1,得目标化合物Ⅴ-29,收率81%,ESI(M-H)
-=309。
实施例52:目标化合物Ⅴ-30的合成
参考实施例22的步骤,用V-27代替V-1,得到目标化合物Ⅴ-30,ESI(M-H)
-=265。
实施例53:目标化合物Ⅴ-31的合成
参考实施例22的步骤,用V-28代替V-1,得到目标化合物Ⅴ-31,ESI(M-H)
-=249。
实施例54:目标化合物Ⅴ-32的合成
参考实施例22的步骤,用V-21代替V-1,得到目标化合物Ⅴ-32,ESI(M-H)
-=337。
实施例55:目标化合物Ⅴ-33的合成
参考实施例22的步骤,用V-22代替V-1,得到目标化合物Ⅴ-33,ESI(M-H)
-=293。
实施例56:目标化合物Ⅴ-34的合成
参考实施例22的步骤,用V-23代替V-1,得到目标化合物Ⅴ-34,ESI(M-H)
-=277。
实施例57:目标化合物Ⅴ-35的合成
参考实施例22的步骤,用V-20代替V-1,得到目标化合物Ⅴ-35,ESI(M-H)
-=259。
实施例58:目标化合物Ⅴ-36和Ⅴ-37的合成
以V-9a为原料,通过手性柱拆分得到化合物Ⅴ-36和Ⅴ-37。
实施例59:目标化合物Ⅴ-38和Ⅴ-39的合成
以V-10a为原料,通过手性柱拆分得到化合物Ⅴ-38和Ⅴ-39。
实施例60:目标化合物Ⅴ-40和Ⅴ-41的合成
以V-11a为原料,通过手性柱拆分得到化合物Ⅴ-40和Ⅴ-41。
实施例61:目标化合物Ⅴ-42和Ⅴ-43的合成
以V-21为原料,通过手性柱拆分得到化合物Ⅴ-42和Ⅴ-43。
实施例62:目标化合物Ⅴ-44和Ⅴ-45的合成
以V-22为原料,通过手性柱拆分得到化合物Ⅴ-44和Ⅴ-45。
实施例63:目标化合物Ⅴ-46和Ⅴ-47的合成
以V-23为原料,通过手性柱拆分得到化合物Ⅴ-46和Ⅴ-47。
实施例64:目标化合物Ⅴ-48和Ⅴ-49的合成
以V-24为原料,通过手性柱拆分得到化合物Ⅴ-48和Ⅴ-49。
实施例65:目标化合物Ⅴ-50和Ⅴ-51的合成
以V-25为原料,通过手性柱拆分得到化合物Ⅴ-50和Ⅴ-51。
实施例66:本发明公开化合物对ADP诱导体外血小板聚集的抑制作用
以未加入任何试剂或药物的洗涤血小板样品为空白对照组,给药ADP及二甲基亚砜(DMSO)的洗涤血小板样品为阴性对照,给药ADP及上市药物丁苯酞(NBP)的洗涤血小板样品为阳性对照。使用体外血小板聚集试验测定本发明得到化合物对ADP诱导血小板聚集的抑制作用。
本发明化合物对ADP诱导血小板聚集的抑制作用的实验方法如下:
实验材料:
药物:受试药:本发明得到的单体化合物。阳性对照药:丁苯酞购买自上海毕得医药科技有限公司。纯度>95%。
实验动物:SPF级SD雄鼠。饲养于容积为500×350×200mm(长×宽×高)的不锈钢铁丝笼内,每笼不多于5只。试验期间,同一房间区域内不得饲养其他种属的动物。实验动物使用许可证号:SYXK(浙)2012-0178。温度严格控制在18~26℃,湿度40%~70%,日温差不超过4℃,换气次数为>8次/小时,控制光照12小时/黑暗12小时昼夜交替(8:00-20:00光照)。实验动物使用饮水瓶自由饮水,自由摄食。
洗涤血小板样品获得方法:SD大鼠按0.3ml/100g腹腔注射10%水合氯醛进行麻醉,腹主动脉采血,每只动物每次采血量10ml左右,血液置于含有枸橼酸盐葡萄糖抗凝剂(ACD)的离心管中。按血液:ACD体积9:1混匀。120g,25℃离心20min,得上清即富血小板血浆(PRP)。用ACD将PRP稀释制备洗涤血小板,按血:ACD体积1:3混匀,800g;25℃离心10min得沉淀物即为血小板。小心吸取上层清液转移至新的离心管中,下层液体800g离心10分钟,吸取上层液体为无血小板的备用血浆(PPP)。沉淀物用血小板重悬液(Tyrode's buffer)重悬。血细胞计数板计数后用重悬液Tyrode's buffer将血小板稀释到200×10
9个/L。
体外血小板聚集实验:空白对照组:取洗涤血小板样品(290μL)于装有一次性搅拌子的一次性样品杯中室温孵育3min,再放入普利生四通道血小板聚集测试仪孵育孔37℃恒温孵育3min,用PPP调零后,加入诱导剂ADP10μL后(ADP系统浓度为10uM,空白对照组加入10μl生理盐水)检测血小板聚集率,记录300s内的血小板最大聚集率(%)。确认ADP的诱导血小板聚集效应。阴性对照组:去洗涤血小板样品(288μl)于装有一次性搅拌子的一次性样品杯中,加入2μL DMSO,室温孵育3min,再放入普利生四通道血小板聚集测试仪孵育孔37℃恒温孵育3min,用PPP调零后,加入诱导剂ADP10μL后(ADP系统浓度为10uM)检测血小板聚集率,记录300s内的血小板最大聚集率(%)。每组平行三次。阳性对照组及实验组:取洗涤血小板样品(288μl)于装有一次性搅拌子的一次性样品杯中,加入2μL丁苯酞或本发明得到化合物(化合物系统浓度为0.1mM),室温孵育3min,再放入普利生四通道血小板聚集测试仪孵育孔37℃恒温孵育3min,用PPP调零后,加入诱导剂ADP10μL后(ADP系统浓度为10uM)检测血小板聚集率,记录300s内的血小板最大聚集率(%)。每组平行三次。抑制率计算公式:
试验数据由Graphpad Prism提供的数据分析软件进行分析,此处采用单因素分析。得到表1的数据。
表1 本发明公开化合物对ADP诱导血小板聚集的抑制作用
+++表示抑制率数值大于30%
++表示抑制率数值大于20%小于30%
+表示抑制率数值大于10%小于20%
N.S.表示数值小于10%。
由表1可知,0.1mM的本发明公开化合物对于ADP诱导的体外血小板聚集抑制率与阳性药丁苯酞无显著性差异,说明本发明公开化合物与阳性药对血小板聚集的抑制活性相当。
实施例67:本发明公开化合物对OGD/R胎鼠原代皮层神经元细胞的保护作用
以未进行OGD/R造模的正常神经元细胞为对照组,仅进行OGD/R建模而未经药物处理的神经元细胞为模型组,以进行OGD/R建模且使用上市药物丁苯酞(NBP)、BZP处理的神经元细胞为阳性对照,进行OGD/R建模且使用本发明化合物处理的神经元细胞为实验组,采用CCK8法测定本发明得到的化合物对OGD/R造模的胎鼠原代皮层神经元细胞保护作用。
本发明化合物的OGD/R造模的神经元细胞保护作用的药理实验方法如下:
实验材料:
药物:受试药:本发明得到的单体化合物。阳性对照药:丁苯酞、BZP购买自上海毕得医药科技有限公司。纯度>95%。
细胞株:第15天ICR胎鼠大脑皮层神经元。
培养基及添加剂:Neurobasal(NB培养液),B27添加剂,GlutaMax添加剂,DMEM无糖,FBS,美国Gibco公司生产。
培养基配制方法:
NBM/B27培养基-低谷氨酰胺版:若用50mL离心管,则加入45mLNB培养液,0.9mLB27添加剂,1%双抗,11.25μL Glutamax添加剂;
NBM/B27培养基-高谷氨酰胺版:若用50mL离心管,则加入45mLNB培养液,0.9mLB27添加剂,1%双抗,27μL Glutamax添加剂;
药物配制方法:将药物溶于DMSO中制成相应浓度的储备液,并按一定比例用培养基稀释。
细胞获得及培养:
将孕鼠断颈处死,置仰卧位,在其腹部开口,取其子宫。得到胎鼠置于HBSS中,使用手术剪及镊子将其脑去除并分离表面血管膜。
用胰酶及DNA酶37℃下消化细胞25-30min。消化完毕后用10%FBS+DMEM终止消化,随后移至DMEM中。用从大至小口径的移液枪头吹打细胞至无阻力后,收集上清液并离心。离心后弃上清,将沉淀用培养基(NBM/B27培养基-高谷氨酰胺版)稀释至50万个细胞/mL后接种于96孔板中(10万/孔,100μL/孔)。
将所得细胞于37℃、5%CO2细胞培养箱中孵育,每三日半量换液(NBM/B27培养基-低谷氨酰胺版),第七天OGD前2h给药。
给药:将化合物用二甲基亚砜(DMSO)溶解制得20000μM贮备液,用培养基(NBM/B27培养基-低谷氨酰胺版)稀释,得到含有药液的培养基(20μM和2μM),每孔吸去培养基50μL,加入含有药液的培养基50μL,终浓度为10μM,1μM共同于37℃、5%CO2细胞培养箱中孵育2小时,空白组及造模组不换液。
造模:
ODG:2小时后,将细胞培养基更换为无糖DMEM(事先放置于厌氧箱20min除去其中O2,洗三次),放入厌氧箱(95%N2+5%CO
2),37℃培养2h。
R:2小时后,将从厌氧箱中取出,细胞培养基更换为NBM/B27培养基-低谷氨酰胺版。于37℃、5%CO
2细胞培养箱中孵育24h。
用CCK8试剂盒测定细胞活力:每孔加入10盒测定细胞活溶液后于37℃、5%CO
2细胞培养箱中孵育2h,450nm测定各孔吸光度。
细胞存活率的计算公式为:细胞存活率%=(用药组OD值-空白孔背景OD值)/(对照组细胞OD值-空白孔背景OD值)D景背景的。
试验数据由Graphpad Prism提供的数据分析软件进行分析,此处采用单因素分析。得到表2的数据,同时得到图2结果。
表2 化合物对OGD/R造模的胎鼠原代皮层神经元细胞保护作用
注:+:0-0.2,++:0.2-0.4,+++:0.4以上
t-test,与对照组相比,####:P<0.0001。
t-test,与模型组相比,****:P<0.0001,***:P<0.001,*:P<0.05。
由表2可知,此次药理实验,对照组与造模组有显著性差异,表明OGD/R造模成功,OGD/R处理后细胞存活率下降;造模组与各给药组均有显著性差异,表明阳性药NBP、BZP与目标化合物均对神经细胞有保护作用,可以提高其存活率。
由图2可知,目标化合物组与NBP组和BZP相比,细胞存活率均较高。其中,Ⅴ-9a-1μM组与NBP-10μM组、BZP-10μM组没有显著性差异;但本发明化合物10μM组与NBP-10μM、BZP-10μM组存在显著性差异,且明显高于NBP-10μM、BZP-10μM组,可以认为本发明化合物在低浓度下便展现了较高的神经保护作用。
实施例68:本发明公开化合物对神经母细胞瘤细胞(N2A)OGD/R损伤的保护作用
神经母细胞瘤细胞诱导分化成神经元样细胞后进行OGD/R造模。氧糖剥夺4小时后加入含血清含糖的DMEM培养基实现再灌注,并对再灌注后24h的细胞进行后续分析。实验分为8组:Control组、模型组、阳性药NBP-10μM组、V-9a 0.1μM组、V-9a 1μM组、V-9a 10μM组、V-9a 100μM组。各组对应的药物于再灌注时加入细胞培养基中。
使用Cell Counting Kit-8(CCK-8)评估细胞活力,结果见图3,由结果显示OGD/R造模后模型组细胞活力显著降低,而V-9a和NBP都可显著提高缺血缺氧后神经元样细胞的活性,且V-9a 10μM组提高组保护作用优于NBP。细胞质LDH的释放表明细胞膜完整性丧失,代表细胞死亡。OGD/R造模后模型组细胞LDH释放明显增加,而V-9a和NBP都可显著减少神经元样细胞的LDH释放。
实施例69:本发明公开化合物在大鼠口服药代动力学中的性质
实验设计:SD大鼠3只(雄性),按下表进行实验。
样品采集:每只动物每次通过眼眶取0.10mL血液,EDTAK2抗凝,采集时间点为给予受试物后15min,30min,1h,2h,4h,6h,8h。血液样本采集后置于冰上,并于30分钟之内离心分离血浆(离心条件:5000转/分钟,10分钟,4℃)。分析前存放于-80℃。
LC-MS/MS条件:
液相方法:色谱柱:ACQUITY BEH C18 2.1x50mm 1.7μm
流动相A:0.1%甲酸水;流动相B:乙腈;流速:0.35mL/min
流动相比例随时间变化:
进样量:10μL
质谱方法:毛细管电压:3.5kV,脱溶剂气温度:500℃,脱溶剂气流量:1000L/Hr,锥孔气流量:50L/Hr。
药物浓度标准曲线绘制:取受试化合物储备液用50%甲醇水稀释成含各化合物浓度分别为40、100、200、400、1000、2000、4000、10000、20000ng/mL的标准工作液,120、1200、12000ng/mL的质控工作液;分别取47.5μL空白基质中加入2.50μL的标准曲线工作液和质控工作液,配置成含药物浓度为2.00、5.00、10.00、20.00、50.00、100.00、200.00、500.00、1000.00ng/mL的标曲和浓度为6.00、60.00和600.00ng/mL的质控样本,分别加入200μL的乙腈(含氯雷他定1ng/mL),涡旋振荡3min后,20000rcf,4℃离心10min,取上清液进行LC-MS/MS分析。
血药浓度测定:取血浆样品50μL,加入200μL的乙腈(含氯雷他定1ng/mL),涡旋振荡3min后,20000rcf,4℃离心10min,取上清液进行LC-MS/MS分析。通过标准曲线计算得到血药浓度并通过Das 2.0计算得到Cmax(ug/L)和AUC
0-t(hr*ng/mL),如表3。
表3 受试化合物的部分药代动力学参数(IG10mg/kg)
注:NA:低于检测限,无法计算
由表3可知,本发明公开化合物口服给药时,在SD大鼠血浆中可达到较高的血药浓度和暴露量,相比丁苯酞和BZP有明显优势。实验结果表明本发明公开化合物能成为理想的口服药物候选分子。
实施例70:本发明公开化合物在脑卒中动物模型中的药效作用
采用线栓法短暂性大脑中动脉阻塞构建局灶性脑缺血动物模型,测试V-9a的体内抗卒中活性。实验应用SPF级C57小鼠,10周龄,健康雄性,体重为22-25g。实验分五组:MCAO+Saline组(1ml saline)、MCAO+NBP(10mg/kg,i.v)、MCAO+V-9a(3mg/kg,i.v)、MCAO+V-9a(10mg/kg,i.v)、MCAO+V-9a(30mg/kg,i.v),每组10只动物。各组动物在MCAO复灌后立即静脉注射给药1次。24小时后进行行为学评分、激光散斑成像观察脑血流恢复情况,以及脑组织TTC染色。
与模型组相比,给NBP和V-9a均可降低小鼠神经学评分,行为学损伤症状明显改善,TTC染色显示V-9a给药后小鼠脑梗死体积明显减小,且V-9a的缺血保护作用呈剂量依赖性。并且30mg/kg V-9a给药组小鼠脑梗死体积较10mg/kg NBP给药组小鼠显著降低。提示V-9a高剂量对脑缺血损伤的保护作用优于NBP。
综上所述,本发明所涉及的四氮唑类衍生物具有广阔的预防和对抗心脑血管性疾病、改善心脑血管循环障碍或抗血栓的药物应用前景。
Claims (11)
- 根据权利要求1所述的四氮唑类衍生物,其特征在于,所述的四氮唑类衍生物包括如下化合物中的一种或多种:1-(4-溴-2-(1-甲基-1H-四唑-5-基)苯基)戊-1-醇;1-(6-溴-2-(1H-四唑-5-基)吡啶-3-基)戊-1-醇;1-(6-溴-2-(1-甲基-1H-四唑-5-基)吡啶-3-基)戊-1-醇;1-(4-氯-2-(1-甲基-1H-四唑-5-基)苯基)戊-1-醇;1-(6-氯-2-(1H-四唑-5-基)吡啶-3-基)戊-1-醇;1-(6-氯-2-(1-甲基-1H-四唑-5-基)吡啶-3-基)戊-1-醇;1-(4-氟-2-(1-甲基-1H-四唑-5-基)苯基)戊-1-醇;1-(6-氟-2-(1H-四唑-5-基)吡啶-3-基)戊-1-醇;1-(6-氟-2-(1-甲基-1H-四唑-5-基)吡啶-3-基)戊-1-醇;1-(2-(1-甲基-1H-四唑-5-基)苯基)戊-1-醇;1-(2-(1H-四唑-5-基)吡啶-3-基)戊-1-醇;1-(2-(1-甲基-1H-四唑-5-基)吡啶-3-基)戊-1-醇;1-(4-氨基-2-(1H-四唑-5-基)苯基)戊-1-醇;1-(4-氨基-2-(1-甲基-1H-四唑-5-基)苯基)戊-1-醇;1-(4-硝基-2-(1H-四唑-5-基)苯基)戊-1-醇;1-(4-硝基-2-(1-甲基-1H-四唑-5-基)苯基)戊-1-醇;1-(2-(1H-四唑-5-基)-4-(三氟甲基)苯基)戊-1-醇;1-(2-(1-甲基-1H-四唑-5-基)-4-(三氟甲基)苯基)戊-1-醇;1-(4-溴-2-(1H-四唑-5-基)苯基)戊-1-醇;1-(4-溴-2-(1H-四唑-5-基)苯基)丁-1-醇;1-(4-溴-2-(1-甲基-1H-四唑-5-基)苯基)丁-1-醇;1-(4-溴-2-(1H-四唑-5-基)苯基)己-1-醇;1-(4-溴-2-(1-甲基-1H-四唑-5-基)苯基)己-1-醇;1-(4-氯-2-(1H-四唑-5-基)苯基)戊-1-醇;1-(4-氯-2-(1H-四唑-5-基)苯基)丁-1-醇;1-(4-氯-2-(1-甲基-1H-四唑-5-基)苯基)丁-1-醇;1-(4-氯-2-(1H-四唑-5-基)苯基)己-1-醇;1-(4-氯-2-(1-甲基-1H-四唑-5-基)苯基)己-1-醇;1-(4-氟-2-(1H-四唑-5-基)苯基)戊-1-醇;1-(4-氟-2-(1H-四唑-5-基)苯基)丁-1-醇;1-(4-氟-2-(1-甲基-1H-四唑-5-基)苯基)丁-1-醇;1-(4-氟-2-(1H-四唑-5-基)苯基)己-1-醇;1-(4-氟-2-(1-甲基-1H-四唑-5-基)苯基)己-1-醇;1-(2-(1H-四唑-5-基)苯基)戊-1-醇;1-(2-(1H-四唑-5-基)苯基)丁-1-醇;1-(2-(1-甲基-1H-四唑-5-基)苯基)丁-1-醇;1-(2-(1H-四唑-5-基)苯基)己-1-醇;1-(2-(1-甲基-1H-四唑-5-基)苯基)己-1-醇;1-(5-溴-2-(1H-四唑-5-基)苯基)戊-1-醇;1-(5-溴-2-(1H-四唑-5-基)苯基)己-1-醇或上述化合物的其他光学异构体;或上述化合物药学上可接受的盐或溶剂合物;或其光学异构体药学上可接受的盐或溶剂合物。
- 根据权利要求1所述的四氮唑类衍生物,其特征在于,所述药学上可接受的盐是与下列碱中的一种或多种所形成的盐:氢氧化钠,氢氧化钾,氢氧化锂,甲醇钠,甲醇钾,乙醇钠,乙醇钾,三乙胺,叔丁胺。
- 根据权利要求1所述的四氮唑类衍生物,其特征在于,所述的四氮唑类衍生物包括:1-(6-溴-2-(1H-四唑-5-基)吡啶-3-基)戊-1-醇钠盐1-(6-溴-2-(1H-四唑-5-基)吡啶-3-基)戊-1-醇钾盐1-(6-溴-2-(1H-四唑-5-基)吡啶-3-基)戊-1-醇锂盐1-(6-溴-2-(1H-四唑-5-基)吡啶-3-基)戊-1-醇三乙胺盐1-(6-溴-2-(1H-四唑-5-基)吡啶-3-基)戊-1-醇叔丁胺盐1-(2-(1H-四唑-5-基)-4-(三氟甲基)苯基)戊-1-醇钠盐1-(2-(1H-四唑-5-基)-4-(三氟甲基)苯基)戊-1-醇钾盐1-(2-(1H-四唑-5-基)-4-(三氟甲基)苯基)戊-1-醇锂盐1-(2-(1H-四唑-5-基)-4-(三氟甲基)苯基)戊-1-醇三乙胺盐1-(2-(1H-四唑-5-基)-4-(三氟甲基)苯基)戊-1-醇叔丁胺盐1-(4-氨基-2-(1H-四唑-5-基)苯基)戊-1-醇钠盐1-(4-氨基-2-(1H-四唑-5-基)苯基)戊-1-醇钾盐1-(4-氨基-2-(1H-四唑-5-基)苯基)戊-1-醇锂盐1-(4-氨基-2-(1H-四唑-5-基)苯基)戊-1-醇三乙胺盐1-(4-氨基-2-(1H-四唑-5-基)苯基)戊-1-醇叔丁胺盐1-(4-溴-2-(1H-四唑-5-基)苯基)戊-1-醇钠盐1-(4-溴-2-(1H-四唑-5-基)苯基)戊-1-醇钾盐1-(4-溴-2-(1H-四唑-5-基)苯基)戊-1-醇锂盐1-(4-溴-2-(1H-四唑-5-基)苯基)戊-1-醇三乙胺盐1-(4-溴-2-(1H-四唑-5-基)苯基)戊-1-醇叔丁胺盐或上述化合物的其他光学异构体;或上述化合物的药学上可接受的溶剂合物。
- 根据权利要求1所述的四氮唑类衍生物,其特征在于,所述的四氮唑类衍生物包括:(R)-1-(4-溴-2-(1H-四唑-5-基)苯基)戊-1-醇(S)-1-(4-溴-2-(1H-四唑-5-基)苯基)戊-1-醇(R)-1-(4-氯-2-(1H-四唑-5-基)苯基)戊-1-醇(S)-1-(4-氯-2-(1H-四唑-5-基)苯基)戊-1-醇(R)-1-(4-氟-2-(1H-四唑-5-基)苯基)戊-1-醇(S)-1-(4-氟-2-(1H-四唑-5-基)苯基)戊-1-醇(R)-1-(4-溴-2-(1H-四唑-5-基)苯基)己-1-醇(S)-1-(4-溴-2-(1H-四唑-5-基)苯基)己-1-醇(R)-1-(4-氯-2-(1H-四唑-5-基)苯基)己-1-醇(S)-1-(4-氯-2-(1H-四唑-5-基)苯基)己-1-醇(R)-1-(4-氟-2-(1H-四唑-5-基)苯基)己-1-醇(S)-1-(4-氟-2-(1H-四唑-5-基)苯基)己-1-醇(R)-1-(5-溴-2-(1H-四唑-5-基)苯基)戊-1-醇(S)-1-(5-溴-2-(1H-四唑-5-基)苯基)戊-1-醇(R)-1-(5-溴-2-(1H-四唑-5-基)苯基)己-1-醇(S)-1-(5-溴-2-(1H-四唑-5-基)苯基)己-1-醇或上述化合物的其他光学异构体;或上述化合物的药学上可接受的溶剂合物。
- 根据权利要求7所示的四氮唑类衍生物的制备方法,其特征在于,所述酰基保护试剂为乙二醇,脱保护试剂为盐酸。
- 根据权利要求7所示的四氮唑类衍生物的制备方法,其特征在于,所述化合物(1)与酰基保护试剂反应的温度为110~130℃;所述化合物(2)与叠氮钠反应的温度为90~110℃。
- 一种药物组合物,其特征在于,所述药物组合物包含至少一种活性组分以及一种或多种药学上可接受的载体或赋形剂,所述的活性组分为权利要求1~9任一项所述的四氮唑类衍生物。
- 一种权利要求1~9任一项所述四氮唑类衍生物在制备预防和对抗心脑血管性疾病、改善心脑血管循环障碍或抗血栓的药物中的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011231596.8A CN112457265A (zh) | 2020-11-06 | 2020-11-06 | 四氮唑类衍生物、制备、含其的药物组合物及其应用 |
CN202011231596.8 | 2020-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022095965A1 true WO2022095965A1 (zh) | 2022-05-12 |
Family
ID=74825898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/129024 WO2022095965A1 (zh) | 2020-11-06 | 2021-11-05 | 四氮唑类衍生物、制备、含其的药物组合物及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN112457265A (zh) |
WO (1) | WO2022095965A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112457265A (zh) * | 2020-11-06 | 2021-03-09 | 浙江大学 | 四氮唑类衍生物、制备、含其的药物组合物及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1382682A (zh) * | 2002-05-09 | 2002-12-04 | 中国医学科学院药物研究所 | 2-(α-羟基戊基)苯甲酸盐及其制法和用途 |
CN101402565A (zh) * | 2008-11-14 | 2009-04-08 | 郑州大学 | 卤代2-(a-羟基戊基)苯甲酸盐及其制法和用途 |
CN104086399A (zh) * | 2013-07-17 | 2014-10-08 | 郑州大学 | 5-溴-2-(α-羟基戊基)苯甲酸钠盐的不同晶型及其制备方法 |
CN109678715A (zh) * | 2018-11-28 | 2019-04-26 | 中国药科大学 | 2-(1-酰氧正戊基)苯甲酸与碱性氨基酸或氨基胍形成的盐、其制备方法及用途 |
CN111943898A (zh) * | 2019-05-17 | 2020-11-17 | 浙江大学 | 苯联四氮唑类衍生物、制备、含其的药物组合物及其应用 |
CN112457265A (zh) * | 2020-11-06 | 2021-03-09 | 浙江大学 | 四氮唑类衍生物、制备、含其的药物组合物及其应用 |
-
2020
- 2020-11-06 CN CN202011231596.8A patent/CN112457265A/zh active Pending
-
2021
- 2021-11-05 CN CN202111308018.4A patent/CN114436985A/zh active Pending
- 2021-11-05 WO PCT/CN2021/129024 patent/WO2022095965A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1382682A (zh) * | 2002-05-09 | 2002-12-04 | 中国医学科学院药物研究所 | 2-(α-羟基戊基)苯甲酸盐及其制法和用途 |
CN101402565A (zh) * | 2008-11-14 | 2009-04-08 | 郑州大学 | 卤代2-(a-羟基戊基)苯甲酸盐及其制法和用途 |
CN104086399A (zh) * | 2013-07-17 | 2014-10-08 | 郑州大学 | 5-溴-2-(α-羟基戊基)苯甲酸钠盐的不同晶型及其制备方法 |
CN109678715A (zh) * | 2018-11-28 | 2019-04-26 | 中国药科大学 | 2-(1-酰氧正戊基)苯甲酸与碱性氨基酸或氨基胍形成的盐、其制备方法及用途 |
CN111943898A (zh) * | 2019-05-17 | 2020-11-17 | 浙江大学 | 苯联四氮唑类衍生物、制备、含其的药物组合物及其应用 |
CN112457265A (zh) * | 2020-11-06 | 2021-03-09 | 浙江大学 | 四氮唑类衍生物、制备、含其的药物组合物及其应用 |
Non-Patent Citations (1)
Title |
---|
TURGUT, GURBET ÇELIK ET AL.: "Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 25, no. 2, 18 November 2016 (2016-11-18), pages 483 - 495, XP029862954, DOI: 10.1016/j.bmc.2016.11.015 * |
Also Published As
Publication number | Publication date |
---|---|
CN114436985A (zh) | 2022-05-06 |
CN112457265A (zh) | 2021-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10000489B2 (en) | Compounds αvβ6 integrin antagonists | |
JP4054368B2 (ja) | 置換メチルアリール又はヘテロアリールアミド化合物 | |
JP4490911B2 (ja) | β−2アゴニストとしてのインドール誘導体 | |
TW200906403A (en) | Pyridine derivatives | |
AU2014267974B2 (en) | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof | |
WO2016150255A1 (zh) | 稠环衍生物、其制备方法、中间体、药物组合物及应用 | |
KR20070004676A (ko) | 알파4 인테그린의 길항제로서의 피리다지논 | |
TW201000460A (en) | Amide compound | |
KR20090122931A (ko) | 오르니틴 유도체 | |
KR20070001976A (ko) | 알파4 인테그린의 길항제로서의 피리다지논 우레아 | |
BRPI0712332A2 (pt) | composto e derivados farmaceuticamente aceitáveis dos mesmos, composição farmacêutica, método de antagonização de um receptor dp-2, e, uso de um composto | |
JPH072840A (ja) | ロイコトリエン生合成の阻害物質としての(アザアリールメトキシ)インドール | |
JP2017538712A (ja) | 細胞壊死の抑制剤及びそれに関連する方法 | |
PT1856093E (pt) | Sal hcl de (2r,4ar,10br)-6-(2,6-dimetoxipiridin-3-il)-9-etoxi- 8-metoxi-1,2,3,4,4a,10b-hexa-hidrofenantridin-2-ol | |
WO2015139619A1 (zh) | 作为RORγ调节剂的化合物 | |
WO2022095965A1 (zh) | 四氮唑类衍生物、制备、含其的药物组合物及其应用 | |
WO1998022442A2 (en) | Pharmaceutical compositions comprising diaryl-cyclomethylenpyrazole compounds and their use as cyclooxygenase i (cox 1) inhibitors | |
US9708307B2 (en) | Heterocyclic acetamide compound | |
JPH0656831A (ja) | ロイコトリエン生合成阻害剤としての(キノリン−2−イルメトキシ)ヘテロテトラヒドロカルバゾール類 | |
JP2000509732A (ja) | 神経変性状態およびcns外傷関連状態の処置のための3−ヘテロアリール−4(3h)−キナゾリノン類のアトロプ異性体 | |
CN115803029A (zh) | 作为trpa1抑制剂的四唑衍生物 | |
TW202106675A (zh) | 二胺基嘧啶類化合物或其水合物的固體形式及其製備方法和用途 | |
WO2022116968A1 (zh) | 一种新型n-杂环bet溴结构域抑制剂、其制备方法及医药用途 | |
CA3080091C (en) | Amorphous pyrrolidine derivative as ppar agonist and preparation method thereof | |
US20100222394A1 (en) | Method for producing pyrazol-3-yl-benzamide derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21888657 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21888657 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21888657 Country of ref document: EP Kind code of ref document: A1 |